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BIOMOLECULAR COATING FOR IMPLANTS 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
2 
cades that may ultimately confound phenotypic responses 
and interfere with controlled cell function. 
This application is a divisional ofU.S. Ser. No. 11/857,819 
filed Sep. 19, 2006, which claims priority to U.S. Ser. No. 
60/826, 193 filed Sep. 19, 2006, both of which are incorpo-
rated herein by reference in their entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
The most common peptide-based strategy involves the sur-
face deposition of peptides containing the Arg-Gly-Asp 
(RGD) sequence, which mediates cell attachment to several 
matrix proteins, including fibronectin, vitronectin, osteopon-
tin, and bone sialoprotein. However, these bio-inspired strat-
egies have yielded marginal increases in implant integration 
and mechanical fixation. Because RGD is recognized by a 
10 large number of integrins in numerous cell types, this 
approach lacks specificity for particular targeted integrin sig-
naling events and results in non-discriminatory attachment of 
cells to the RGD-coated surfaces. 
This invention was made with Government Support under 
Grant No. ROI EB-004496 by the National Institutes of 15 
Health, Grant No. DTD 000207 awarded by the Arthritis 
Foundation, and Grant No. ERC EEC-9731643 awarded by 
the National Science Foundation. The Government has cer-
tain rights in the invention. 
20 
REFERENCE TO SEQUENCE LISTING 
The Sequence Listing submitted Feb. 13, 2012, as a text file 
named "GTRC_3967 _ST25.txt," created on Aug. 25, 2011, 
and having a size of 6,318 bytes is hereby incorporated by 25 
reference. 
TECHNICAL FIELD 
Therefore, it is an object of the invention to provide meth-
ods and compositions to improve implant integration in vivo. 
It is still another object to provide devices and implants 
coated with biomolecular compositions for increasing tissue 
integration of the device. 
It is yet another object to provide methods and composi-
tions for treating bone defects, bone disorders, or diseases of 
the bone. 
SUMMARY 
Methods and compositions are provided for improving 
device integration into tissue, treating tissue disorders and 
defects such as bone defects, bone disorders, or diseases of 
the bone. One aspect provides methods and compositions for 
This disclosure is generally directed to biomolecular coat-
ings for biomedical devices and implants and methods for 
improving device integration into tissues and methods for 
treating tissue defects or diseases including, but not limited to 
bone defects, disorders, or diseases. 
30 improving implant integration into tissue. The tissue can be 
osseous, cardiovascular, skin, liver or kidney tissue. One 
aspect provides methods and compositions for improving 
tissue growth on or in an implant, or a combination thereof. 
Another aspect provides a device, for example an implant 
BACKGROUND 
35 having an integrin-specific ligand in an amount effective to 
promote tissue growth, implant integration, or a combination 
thereofin vivo. Another aspect provides a device, for example 
an orthopaedic, dental, cardiovascular, liver, or kidney device 
having an a2 ~ 1 integrin ligand, an a5 ~ 1 integrin ligand, or a 
Upon implantation, synthetic materials elicit an inflamma-
tory response that results in a foreign body reaction and 
fibrous encapsulation. The foreign body reaction severely 
limits device integration and in vivo performance of numer-
ous biomedical devices, including chemical biosensors, elec-
trical leads/electrodes, therapeutic delivery systems, and 
orthopaedic and cardiovascular prostheses. Extensive efforts 
have concentrated on surface treatments and coatings to 
improve host tissue-implant integration. For instance, current 
orthopaedic and dental implant surface technologies focus on 
rough/porous coatings for bone ingrowth and bone-bonding 
ceramic coatings to promote integration with the surrounding 
bone. However, while these approaches are generally sue- 50 
cessful, they can be restricted by slow rates of osseointegra-
tion and poor mechanical anchorage in challenging clinical 
cases, such as those associated with large bone loss and poor 
bone quality. Since the extracellular matrix controls cell 
adhesion and function, recent biomimetic strategies have 
focused on the immobilization of matrix components, includ-
ing native proteins, peptide sequences, or synthetic deriva-
tives based on matrix molecules. Full-length extracellular 
matrix proteins are attractive biomimetic targets for function-
alizing orthopaedic implant surfaces in order to promote heal- 60 
ing, bone formation, and implant fixation. However, these 
full- length protein strategies are limited by lack of specificity 
for particular cellular receptors and downstream signaling 
events and thus allow minimal control over cell and tissue 
responses. In addition, native ECM proteins often have bind-
ing sites for other ligands, such as fibrinogen or von Will-
ebrand factor. Such ligands trigger separate signaling cas-
40 combination thereof coated on a surface of the device. Rep-
resentative a2 ~ 1 integrin ligands include, but are not limited 
to, a peptide having at least 80% sequence identity to 
GGYGGGPC(GPP)5 GFOGER(GPP)5 GPC (SEQ ID NO:l, 
referred to herein as "GFOGER peptide"). Representative 
45 a5 ~ 1 integrin ligands include, but are not limited to FNIII7 _10 . 
In certain aspects, the integrin ligand is applied to the surface 
of the device in an amount effective to promote tissue forma-
tion, device integration, or both in vivo relative to a control. A 
control includes a similar device without the integrin ligand. 
Another aspect provides a method for improving implant 
integration by coating the surface of the implant with an a2~ 1 
integrin ligand, an a5 ~ 1 integrin ligand, or a combination 
thereof The integrin ligand can be passively adsorbed to the 
surface of the implant. Typically, the implant is made of metal 
55 such as clinical grade titanium (Ti) or a polymer, for example 
polycaprolactone. In other embodiments, the integrin ligand 
is coupled to the surface of the device by a linker. A repre-
sentative linker includes, but is not limited to, self-assembled 
monolayers (SAMs) of alkanethiols. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a bar graph showing the fraction of adherent cells 
on Ti surfaces adsorbed with "GFOGER peptide" 
65 (GGYGGGPC(GPP)5GFOGER(GPP)5GPC, SEQ ID 
NO:l), adsorbed with linear "RGD peptide" (GRGDSPC, 
SEQ ID N0:3), adsorbed fetal bovine serum (10% in PBS), 
US 8,445,006 B2 
3 
and non-adhesive blocked Ti in the presence or absence of 
blocking antibodies against alpha2 or alpha V integrin sub-
unit. 
FIG. 2A is a bar graph showing amount ofRunx2 mRNA 
expression (fmol transcription/µg) in cells cultured on 5 
GFOGER peptide (SEQ ID NO: 1 )-coated surfaces or Ti sur-
faces. 
4 
SI-ATRP ofpoly(OEGMA) brushes; (3) functionalization of 
OH groups with 4-nitrophenyl chloroformate; and ( 4) peptide 
tethering. 
FIG. 12B presents FITR spectra of the steps in FIG. 12A: 
FIG. 2B is a bar graph showing amount of osteocalcin 
mRNA (fmol transcription/µg) in cells cultured on GFOGER 
peptide (SEQ ID NO: 1 )-coated surfaces or Ti surfaces. 
FIG. 2C is a bar graph showing amount of bone sialopro-
tein mRNA (fmol transcription/µg) in cells cultured on 
GFOGER peptide (SEQ ID NO: 1 )-coated surfaces or Ti sur-
faces. 
(1) mono layer of silane initiator (ester C=O, 1738 cm- 1 ) 
[presence of bromine was demonstrated by XPS (not 
shown)]; (2) SI-ATRP of poly(OEGMA) brushes (poly-
methacrylateC=O, 1730 cm- 1); (3) functionalizationofOH 
groups with 4-nitrophenyl chloroformate (carbonate C=O, 
10 1770 cm- 1); and (4) peptide tethering (amide C=O, 1670 
cm- 1). 
FIG. 3A is a bar graph showing alkaline phosphatase activ- 15 
ity (nmol/min/mg protein) by cells cultured on GFOGER 
peptide (SEQ ID NO: 1 )-coated surfaces compared to cells 
cultured on uncoated titanium surfaces. 
FIG. 3B is a bar graph showing ca+2 content (µg/well) in 
rat bone marrow stromal cultures on surfaces coated with 20 
GFOGER peptide (SEQ ID NO: 1) or uncoated Ti surfaces. 
FIG. 12C is a line graph of tethered densities of RGD 
peptide (SEQ ID N0:3) and FNIII7 _10 (fmol/cm2 ) versus 
coating concentration (µg/ml) of RGD peptide (SEQ ID 
N0:3) or FNIII7 _10 . (hyperbolic curve fit, R2 =0.95). 
FIG. 12D is a line graph of antibody binding (fluorescence 
units) versus FNIII7 _10 surface density (fmol/cm2 ). FNIII7 _10 
activity was detected on the NPC-modified poly(OEGMA) 
brushes (but not the unmodified brushes). 
FIG. 13A is a panel ofbar graphs showing fraction ofbone 
marrow stromal cell adhesion to engineered surfaces medi-
ated by integrin receptors as demonstrated by blocking anti-
bodies against integrin subunits alpha5 or alphaV. Ti-serum 
FIG. 4 is diagram of a representative cylindrical titanium 
implant rod with tapered stop collar ( 401) and transverse hole 
(403) for pull-out mechanical testing. The metal is ASTM 
F67 Grade 4 commercially pure titanium. 
FIG. SA is a bar graph showing percent bone-implant con-
tact of GFOGER peptide (SEQ ID NO: 1) treated; collagen 
treated or untreated control implants. 
25 surface: * vs. no antibody control (p<0.01); RGD tethered 
surface: t vs. no antibody control (p<0.01 ); FNIII7 _10 tethered 
surface: t vs. no antibody control (p<0.005). 
FIG. SB is a bar graph showing pull-out force (N) of 
GFOGER peptide (SEQ ID NO: 1 )-treated, collagen-treated, 30 
or untreated control surfaces. 
FIG. 6A is a line graph of the relative fluorescence intensity 
of bound antibody versus coating concentration (µg/ml) of 
passively adsorbed pFN and FNIII7 _10. 
FIG. 6B shows SPR measurements on streptavidin-coated 35 
chips demonstrating successful biotinylation of FNIII7 _10 . 
They-axes are relative units and surface density (ng/cm2 ). 
FIG. 7 is a line graph of surface density (fmol/cm2 ) of 
FNIII7 _10 , RGD peptide (SEQ ID N0:3), and "RGD-PH-
SRN" (GRGDG13PHSRN, SEQ ID N0:4) tethered to 2% 40 
EGcCOOH:EG3 SAM surfaces as a function of coating con-
centration (µg/ml) determined by surface plasmon resonance 
(SPR). 
FIG. 8 is a line graph showing MC3T3-El cell adhesion 
fraction to SAMs presenting controlled densities ofbioadhe- 45 
sive ligands FNIII7 _10, RGD peptide (SEQ ID N0:3), or 
RGD-PHSRN (SEQ ID N0:4). 
FIG. 9A is a panel of bar graphs showing adherent cell 
fraction on surfaces coated with FNIII7 _10, RGD peptide 
(SEQ ID N0:3), or RGD-PHSRN (SEQ ID N0:4). Surfaces 50 
presenting FNIII7 _10 display integrin binding specificity com-
pared to RGD supports. 
FIG. 9B is a bar graph ofFAKkinase activation (pY-FAK/ 
total FAK) in cells interacting with FNIII7 _10-tethered sur-
faces compared to the RGD-functionalized supports using 55 
antibodies pY397 or pY576. 
FIG. 10 is a bar graph showing percent BrdU incorporation 
(BrdU +cells/total cells) for MC3 T3-El cells cultured for 20 h 
FIG. 13B is a bar graph showing normalized intensity due 
to binding of alpha5betal integrin to FNIII7 _10 tethered 
brushes; RGD tethered brushes; or Ti support (p<0.01) using 
a crosslinking/extraction/reversal procedure for stromal cells 
plated on ligand-tethered brush surfaces of equimolar density. 
FIG. 13C is a bar graph showing normalized intensity due 
to binding of alphaV integrin to FNIII7 _10 tethered brushes 
(p<0.006), RGD tethered brushes, or Ti support using a 
crosslinking/extraction/reversal procedure for stromal cells 
plated on ligand-tethered brush surfaces of equimolar density. 
FIG. 13D is a panel of bar graph of FAK activation on 
equimolar ligand-tethered brush surfaces and serum-treated 
titanium. Relative levels of phospho-Y in FAK in the presence 
or absence of integrin blocking antibodies are shown. Acti-
vation levels for Y397 and Y576 were higher on FNIII7 _10-
tethered brushes than RGD-functionalized and Ti-serum sup-
ports (p<0.01 ). Y861 phosphorylation levels were reduced in 
FNIII7 _10-functionalized titanium relative to the other sur-
faces (p<0.03). Integrin blocking antibodies selectively 
reduced FAK phosphorylation. Y397: t vs. no antibody con-
trol (p<0.04); Y576: t vs. no antibody control (p<0.05); 
Y861: t vs. no antibody control (p<0.05). 
FIG. 14A is a bar graph showing gene expression levels for 
Runx2 on Ti, RGD-tethered or FNIII7 _10-tethered surfaces. 
FIG. 14B is a bar graph showing gene expression levels for 
osteocalcin on Ti, RGD-tethered or FNIII7 _10-tethered sur-
faces. 
FIG. 14C is a bar graph showing gene expression levels for 
bone sialprotien on Ti, RGD-tethered or FNIII7 _10-tethered 
surfaces. 
on RGD peptide (SEQ ID N0:3) and FNIII7 _10 tethered sur-
faces for two different peptide surface densities. 
FIG. llA is a bar graph showing percent bone implant 
contact on surfaces coated with FNIII7 _10, plasma fibronectin 
(pFN), or Ti surfaces. 
FIG. 14D is a bar graph showing alkaline phosphatase 
60 activity of cells culture on Ti, RGD-tethered or FNIII7 _10-
tethered surfaces. 
FIG. llB is bar graph showing pull-out force (N) for 
implants coated with FNIII7 _10 , pFN, or Ti surfaces. 
FIG. 12A shows the steps in tethering a peptide ligand to a 
surface of a device. (1) monolayer of silane initiator; (2) 
65 
FIG. 14E is a bar graph showing calcium content in cells 
cultured on Ti surface, RGD-tethered surface, or FNIII7 _10-
tethered surface. 
FIG. lSA is a bar graph showing percent bone-implant 
contact area for unmodified Ti, RGD-tethered, OEGMA-
functionalized or FNIII7 _10-tethered implants. 
US 8,445,006 B2 
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FIG. 15B is a bar graph of pull-out force (N) for unmodified 
Ti, RGD-tethered, OEGMA-functionalized or FNIII7 _10-
tethered implants 
6 
preferably 85% sequence identity to the reference sequence, 
or most preferably 90% identity to FNIII7 _10 (SEQ ID N0:2). 
FNIII7 _10 is a fibronectin fragment spanning the 7-lOth type 
III repeats of fibronectin. The sequence of fibronectin is FIG.15C is a line graph of pull-out force (N) versus FNIII7 _ 
10 surface density (fmol/cm2 ). 
FIG. 16 is a series of bar graphs of bone volume (mm3 ) in 
polycaprolactone (PCL) scaffolds and PCL scaffolds pas-
sively adsorbed with GFOGER peptide (SEQ ID NO: 1) 
implanted in a non-healing segmental femur defect. 
5 known in the art, see for example Baron, M. et al. (1992). lH 
NMR Assignment and Secondary Structure of the Cell Adhe-
sion Type III Module of Fibronectin. 31: 2068-2073; Baron, 
M. et al. (1990). Structure of the Fibronectin Type I Module. 
Nature. 345: 642-646; Ffrench-Constant C. (1995). Alterna-
lO tive Splicing of Fibronectin-Many Different Proteins but 
Few Different Functions. Exp. Cell. Res. 221: 261-271; Main, 
AL et al. (1992). The Three-Dimensional Structure of the 
Tenth Type III Module of Fibronectin: An Insight into RGD-
DETAILED DESCRIPTION 
I. Compositions 
One embodiment provides a substrate or device, for 
example an orthopaedic or dental device, such as an implant, 
coated with a ligand for a2 ~ 1 integrin, a ligand of a5 ~ 1 inte-
grin, or a combination thereof. In certain embodiments the 
ligand interacts specifically with one integrin. In still other 
embodiments, the ligand is not a complete fibronectin mol-
ecule or is not a complete collagen molecule. 
15 Mediated Interactions. Cell. 71: 671-678. Potts, J R and 
Campbell, ID. (1994). Fibronectin Structure and Assembly. 
Curr. Cell Bio. 6: 648-655; Potts, J R and Campbell, I D. 
(1996). Structure and Function of Fibronectin Modules. 
Matrix Bio. 15: 313-320. 
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A. Integrin Ligands 
The a2~ 1 integrin is highly expressed on osteoblasts and 
other mesenchymal cells and is one of the predominant adhe-
sion receptors for type I collagen. a2 ~ 1 integrin-type I col-
lagen interactions provide crucial signals for the induction of 25 
osteoblastic differentiation and matrix mineralization. For 
example, a2~ 1 -mediated osteoblast adhesion to type I col-
lagen activates Runx2/Cbfal, a transcription factor that regu-
lates osteogenesis. Furthermore, the collagen-a2~ 1 integrin 
interaction induces osteoblastic differentiation in multi potent 30 
bone marrow stromal cells. 
B. Devices 
The disclosed devices include implants, rods, pins, screws, 
braces, plates, prosthesis, tissue engineering scaffolds, or the 
like. The device can be used for joining or fusing parts of one 
or more bones, joining tissue to bone, or joining tissue to 
tissue. The implants can also contain segments prepared from 
natural materials, synthetic materials (including polymers 
and ceramics), metals, metal alloys, or a combination thereof. 
In one embodiment, the implant is made of titanium. As used 
herein, "natural material" means "bone" and includes bone 
harvested from humans or animals. "Bone" may further 
include heterologous, homologous and autologous (i.e., 
xenograft, allograft, autograft) bone derived from, for 
example, fibula, tibia, radius, ulna, humerus, cranium, calca-
An a2 ~ 1 integrin ligand is a substance that binds to a2~ 1 
integrin and optionally activates or inhibits a signal transduc-
tion pathway by binding to a2~ 1 integrin, for example acti-
vating a transcription factor. 
An a5 ~ 1 ligand is a substance that binds to a5 ~ 1 integrin 
and optionally activates or inhibits a signal transduction path-
way by binding to a5 ~ 1 integrin, for example activating a 
transcription factor. A representative a5 ~ 1 integrin ligand 
includes, but is not limited to FNIII7 _10 . 
35 neus, tarsus, carpus, vertebra, patella, ilium, etc. Bone may 
further include one or more bone products which have been 
partially or completely demineralized, prepared for trans-
plantation (e.g., via removal of immunogenic proteins), and/ 
or processed by other techniques. Additionally, the implants 
40 can be prepared from products made from bone, such as 
chips, putties, and other similar bone products. In some 
embodiments, human source bone is preferred for human 
applications. 
The ligand can be a peptide, antibody, or a small organic 
molecule that specifically binds to the specific integrin. A 
small organic molecule refers to a carbon-based molecule 
having a molecular weight of about 500 daltons or less. The 
antibody or an integrin binding fragment thereof can be single 45 
chained, humanized, or chimeric. In certain embodiments, 
the ligand can be a collagen-mimetic peptide, for example a 
stable triple-helical, collagen-mimetic peptide that contains 
the GFOGER (SEQ ID NO: 12) adhesion motif from type I 
collagen that is recognized by the a2 ~ 1 integrin. Circular 50 
dichroism analysis demonstrated that this peptide adopts a 
stable triple-helical conformation similar to the native struc-
ture of type I collagen. An exemplary collagen-mimetic pep-
tide has the following amino acid sequence GGYGGGPC 
(GPP)5GFOGER(GPP)5 GPC (SEQ ID NO: 1, also referred to 55 
herein as "GFOGER peptide") or a variant thereof. Variants 
include peptides having conservative amino acid substitu-
tions. Conservative substitutions refer to changes in amino 
acid sequence which have little or no effect on the function of 
the peptide. 
Another embodiment provides a surface of a device, for 
example an implant, functionalized with an integrin-specific 
ligand for example, GFOGER (SEQ ID NO: 12) or a FNIII7 _10 
recombinant fragment that presents the RGD and PHSRN 
(SEQ ID NO: 11) motifs in the biologically correct, i.e., as 
presented in the naturally occurring protein in vivo, structural 
context. These devices exhibit significantly higher adhesion 
strengths, FAK activations, and cell proliferation rates rela-
tive to supports presenting RGD or RGD-PHSRN (SEQ ID 
N0:4) oligopeptides. Moreover, FNIII7 _10-functionalized 
surfaces display specificity for a5 ~ 1 integrin, while cell adhe-
sion to surfaces presenting RGD or RGD-PHSRN (SEQ ID 
N0:4) is primarily mediated by av~3 integrin. 
In other embodiments the substrate or device can include 
additional therapeutic agents including, but not limited, to 
growth factors, cytokines, morphogens, stem cells, umbilical 
60 cord stem cells, embryonic stem cells, adult stem cells, pluri-
potent cells derived from bone marrow, bone marrow stem 
cells, osteoblasts, osteoclasts, or a combination thereof. The 
cells can be autologous or heterologous. Growth factors 
In another embodiment, the a2~ 1 integrin ligand has a 
sequence with at least 70% sequence identity, or preferably 
80%, or more preferably 85% sequence identity to the refer-
ence sequence, or most preferably 90% identity to 
GGYGGGPC(GPP)5 GFOGER(GPP)5 GPC (SEQ ID NO: 1 ). 65 
Another embodiment provides an a 5 ~ 1 integrin ligand hav-
ing at least 70% sequence identity, or preferably 80%, or more 
include, but are not limited, to the TGF superfamily of growth 
factors, FGF, basic FGF, VEGF, insulin-like growth factor, 
EGF, PDGF, and nerve growth factor. Cytokines include but 
are not limited to IL-1 through IL-13. 
US 8,445,006 B2 
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II. Methods of Use 
8 
Still another embodiment provides a method for adjusting 
the ability of a device to promote bone growth or osseointe-
gration by varying the surface density of integrin-specific 
ligand on the device. Increasing the surface density of the 
integrin-specific ligand increases the ability of the device to 
promote bone growth or osseointegration compared to 
devices having a lower surface density of the integrin-specific 
ligand. Similarly, decreasing the surface density of the inte-
grin-specific ligand on the device decreases the ability of the 
Substrates or devices having an a2~ 1 integrin agonist, an 
a5 ~ 1 integrin agonist, or a combination thereof can be used to 
treat or repair damaged or missing tissue. Tissues that can be 
treated include but are not limited to bone, orthopaedic, den-
tal, cardiovascular, skin, liver, or kidney tissue. For example, 
implants having an a2 ~ 1 ligand or an a5 ~ 1 integrin ligand 
coating can be used to repair fractured or broken bones, to 
fuse or replace bones, or to improve the integration of an 
implant into existing bone tissue. Dental implants can be used 
to treat or repair damaged or missing teeth, and facial bones. 
In certain embodiments, the dental implant can be entirely for 
aesthetic purposes. In addition, implants can be use as a filler 
10 device to promote bone growth or osseointegration. By vary-
ing the surface density of the integrin-specific ligand, devices 
can be tailored to the needs of a specific patient to obtain the 
amount of bone growth or osseointegration needed by the 
to augment or form dental tissue as to support the function of 
natural tissues (such as teeth or bone) or artificial prosthesis. 15 
The device can be configured for implantation into bone, 
orthopaedic, dental, cardiovascular, liver, or kidney tissue. 
patient. 
Another embodiment provides a method of directing cell 
function, for example adhesion, proliferation, or differentia-
tion in vitro by contacting the cell with a substrate coated with 
the disclosed integrin-specific ligands. Specific cell functions 
can be trigged by using substrates having integrin-specific 
Another embodiment provides a method for improving 
implant integration relative to a control by coating a surface of 
an implant with an a2~ 1 integrin agonist, an a5 ~ 1 integrin 
agonist, or a combination thereof and implanting the coated 
implant into tissue of a patient, for example bone tissue. The 
amount of integrin ligand applied to the surface can vary 
depending on the desired outcome. 
20 ligands that trigger the desired cell function. Cell-based 
arrays having a substrate with addressable areas having inte-
grin-specific ligands can be used to assay for pharmaceutical 
and or pathogen/toxins that modulate a cell function triggered 
by the integrin-specific ligand. 
25 III. Methods of Manufacture The implant can be coated with an amount of an a2~ 1 or 
a5 ~ 1 integrin ligand sufficient to promote or induce density-
dependent cell adhesion, focal adhesion kinase signaling, cell 
differentiation, or a combination thereof. The a2~ 1 or a5 ~ 1 
integrin ligand can be passively adsorbed to the implant for 
example by incubating the implant in 20 µg/ml in Dulbecco's 30 
phosphate-buffered saline (PBS) for about 1 hour. Alterna-
tively, the a2~ 1 or a5 ~ 1 integrin ligand can be suspended in a 
vehicle and applied to the implant. Typically, the vehicle is a 
pharmaceutically acceptable vehicle that contains a binding 
agent, for example a gel or thickener, that causes the integrin 35 
ligand to adsorb or adhere to the surface of the implant. 
In other embodiments the disclosed devices and implants 
can be used to treat bone disorders including, but not limited 
to, bone fractures, bone degeneration, osteoporosis, broken 
bones, spinal injuries, chipped bones, herniated vertebral 40 
discs, skull fractures, etc. The devices can also be used to treat 
dental disease including dental diseases that cause loss of 
teeth or loss of bone. 
The disclosed devices can be made by passively adsorbing 
an integrin-specific ligand onto a surface of a device. For 
example, a peptide ligand can be prepared using conventional 
solid phase t-Boc synthesis. 20 µg/ml of the peptide ligand 
can be suspended in Dulbecco's phosphate-buffered saline 
(PBS) and incubated on the titanium surfaces for 1hat22° C. 
Alternatively, the agonists can be attached to a surface of 
the device via a linker. Suitable linkers include, but are not 
limited to self-assembled monolayers (SAMs) of alkanethi-
ols. Mixed alkanethiol SAMs presenting well-defined 
anchoring groups (--COOR) can be used for controlled teth-
ering ofligands in a protein adsorption-resistant background 
(tri(ethylene glycol groups): EG3 ). Peptides can be tethered 
via free amines using NHS/EDC coupling chemistry. For 
example GFOGER (SEQ ID N0:12) or FNIII7 _10 can be 
tethered onto activated/unactivated SAMs with EGcCOOH: 
EG3 .A suitableEG6 -COOH:EG3 solution ratio of0.02 can be 
used. 
One embodiment provides a method for increasing 
osseointegration of prosthetics, devices, screws, pins, tissue-
engineered constructs, scaffolds, and the like by coating one 
or more surfaces of the device with one or more integrin 
agonists, for example GFOGER (SEQ ID NO: 12), FNIII7 _10 , 
Alternatively, the ligand can be tethered to ceramic or 
45 protein coatings on the implants. 
or a combination thereof. 
Methods and Materials 
Cell Isolation and Culture 
Primary bone marrow stromal cells were harvested from 
the femora of young adult male Wistar rats in accordance with 
an IACUC-approved protocol. After excision, hindleg femora 
and tibiae were cleared of soft tissue and rinsed in growth 
medium (a-minimal essential medium supplemented with 
10% fetal bovine serum, 1 % penicillin-streptomycin, and 0.3 
µg/ml amphotericin B). The ends of the long bones were then 
Another embodiment provides a method for treating a bone 50 
defect, bone disorder or bone disease by implanting a device 
into a bone of a host wherein the device is coated with an 
amount ofintegrin ligand effective to promote bone growth. A 
host includes vertebrates, in particular mammals such as 
humans. In certain embodiments, the device is a scaffold, for 
example a polycaprolactone scaffold passively adsorbed with 
GFOGER (SEQ ID NO: 12) or FNIII7 _10. The scaffold need 
not have cells or growth factors included. For example autolo-
gous bone forming cells or BMP proteins are not required, but 
could be included to augment activity, to have increased bone 
growth compared to controls. In certain embodiments, the 
device increases bone growth, bone regeneration, and or bone 
volume by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 
45%, 50%, 55%, 60%, 65%, 70%, or75% or more compared 
55 removed and the marrow space was flushed with culture 
medium (3-5 ml), using a syringe with an 18-gauge needle. 
Marrow isolates were pooled, centrifuged, resuspended in 
growth medium, and seeded for adhesion-dependent selec-
tion on tissue culture polystyrene dishes. Non-adherent 
to a control. An exemplary control is a device without a 
coating of an integrin specific ligand such as GFOGER (SEQ 
ID N0:12) or FNIII7 _10 . 
60 hematopoietic cells were removed during subsequent 
medium exchanges, which occurred every other day. Cells 
were subcultured every two days according to standard tech-
niques. For in vitro osteogenic assays, cells were seeded at 
10,000 cells/cm2 in growth medium. After 24 h, cultures were 
65 maintained in osteogenic medium consisting of growth 
medium supplemented with 50 µg/ml L-ascorbic acid and 3 
mM sodium ~-glycerophosphate. 
US 8,445,006 B2 
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Bacterial and mannnalian cell culture reagents, Dulbec-
co' s phosphate buffered saline (DPBS) and human plasma 
fibronectin (pFN) were obtained from Invitrogen (Carlsbad, 
Calif.). Fetal bovine serum (FBS) was acquired from Hyclone 
(Logan, Utah). "RGD peptide" (GRGDSPC) (SEQ ID N0:3) 5 
was purchased from BACHEM (San Diego, Calif.), and 
"RGD-PHSRN peptide" (GRGDG13PHSRN, SEQ ID N0:4) 
peptide was synthesized by the Emory University Micro-
chemical Facility (Atlanta, Ga.). Peptide tethering reagents, 
N-hydroxysuccinimide (NHS) and N-(3-dimethylaminopro- 10 
pyl)-N-ethylcarbodiimide hydrochloride (EDC), lysozyme 
and DNase were obtained from Sigma-Aldrich (St. Louis, 
Mo.). DH5a and JM109 bacterial cells were purchased from 
Invitrogen and Promega (Madison, Wis.), respectively. The 
XA3 Pinpoint Vector biotinylation expression system and 15 
ECF substrate were obtained from Promega and Amersham 
Pharmacia Biotech (Piscataway, N.J.), respectively. 
electron beam evaporator at a chamber base pressure between 
l-2xl0-6 torr with a deposition rate of 1.5 A/second. The 
GFOGER peptide (SEQ ID NO: 1) was diluted to 20 µg/ml in 
Dulbecco's phosphate-buffered saline (PBS) and incubated 
on the titanium surfaces for 1 h at 22° C. 
Cell Adhesion Assay 
Cell adhesion to functionalized and untreated titanium sur-
faces was measured using a centrifugation assay that applies 
controlled detachment forces. Titanium-coated glass cham-
ber slide wells were reassembled using a silicone-based adhe-
sive and coated with 20 µg/ml GFOGER peptide (SEQ ID 
NO:l) or 20 µg/ml GRGDSPC (SEQ ID N0:3) peptide 
(BACHEM). Control titanium slides were coated with 10% 
FBS (to model serum protein adsorption) or blocking buffer 
(5% non-fat dry milk in PBS to produce a non adhesive 
support). Strama! cells were loaded with the fluorescent dye 
calcein-AM (2 µg/ml, Molecular Probes), detached using 
trypsin+EDTA, and resuspended serum-free in PBS with 2 
mM dextrose. Cells were seeded onto the substrates (10,000 
Antibodies 
Monoclonal HFN7.1 anti-human FN antibody was 
obtained from the Developmental Studies Hybridoma Bank 
(Iowa City, Iowa). Rabbit antibodies against alphaV 
(AB1930) and alpha5 (AB1921) integrin subunits were pur-
chased from Chemicon (Temecula, Calif.), and anti-vinculin 
antibody (V284) was acquired from Upstate Biotechnology 
(Lake Placid, N.Y.). Function-perturbing hamster anti-rat 
beta! integrin (Ha2/5), anti-mouse beta3 (2C9.G2), and anti-
BrdU antibodies were purchased from BD Pharmingen. 
Alkaline phosphatase-conjugated donkey anti-mouse IgG 
(Jackson Innnunoresearch, West Grove, Pa.) was used in 
enzyme linked innnunosorbent assay (ELISA). Alex-
aF!uor488-conjugated goat anti-mouse and anti-rabbit IgG 
antibodies, calcein-AM, and Hoechst 33258 dye were from 
Molecular Probes (Eugene, Oreg.). Monoclonal antibodies 
against total focal adhesion kinase (FAK) (Upstate Biotech-
nology) and specific phosphotyrosine residues in FAK 
(p Y397, p Y576) (Bio Source International, Camarilla, Calif.) 
were used for FAK analysis. Biotinylated anti-rabbit IgG 
(Jackson Immunoresearch) and alkaline phosphatase-conju-
gated anti-biotin antibodies (BN-34, Sigma-Aldrich) were 
used for Western blotting. 
Cell Lines 
MC3T3-El murine innnature osteoblast-like cells (Riken 
Cell Bank, Hirosawa, Japan) were used because of their 
expression of multiple integrins, including alpha5betal, 
alpha2betal, and alpha Vbeta3. Cells were maintained at 3 7° 
C. in a-MEM supplemented with 10% FBS and 1 % penicil-
lin-streptomycin and passaged every 2-3 days via standard 
culture techniques. 
In Vitro GFOGER Peptide (SEQ ID NO: 1) Surface Prepara-
tion 
The peptide GGYGGGPC(GPP)5 GFOGER(GPP)5 GPC 
(SEQ ID NO:l) [O=hydroxyproline] was prepared by the 
Emory University Microchemical Facility using solid phase 
t-Boc synthesis. Peptide was supplied in the purified form as 
a trifluoroacetic acid (TFA) salt and reconstituted at a stock 
concentration of 10 mg/ml in 0.1% TFA. For the in vitro 
assays, glass chamber slides (16-well Lab-Tek Chamber 
Slides, Nalge Nurre) or tissue culture-treated polystyrene 
dishes were coated with 300 A of pure titanium using an 
Gene/Gen Bank 
20 
cells/well) for 1 hat 37° C. For blocking experiments, cells 
were incubated in the presence of 20 µg/ml anti-rat a 2 anti-
body (hamster anti-rat CD49b monoclonal antibody, clone 
Hal/29, BD Pharmingen) or 20 µg/ml anti-rat av antibody 
(mouse anti-rat integrin av chain monoclonal antibody, clone 
25 21, BD Pharmingen). Isotype control antibodies had no effect 
on cell adhesion (data no shown). Initial fluorescence inten-
sity was measured to quantify the number of adherent cells 
prior to application of centrifugal force. After filling the wells 
with PBS/dextrose and sealing with transparent adhesive 
30 tape, substrates were inverted and spun at a fixed speed in a 
centrifuge (Beckman Allegra 6, GH 3.8 rotor) to apply a 
centrifugal force corresponding to 12 g. After centrifugation, 
media was exchanged and fluorescence intensity was read to 
measure remaining adherent cells. For each well, adherent 
35 
cell fraction was calculated as the ratio of post-spin to pre-
spin fluorescence readings. 
Osteoblast-Specific Gene Expression 
Gene expression was analyzed by qRT-PCR. Total RNA 
was isolated at 7 days in culture using the Qiagen RNeasy 
40 RNA isolation kit. During RNA isolation and purification, 
samples were treated with DNaseI (27 Kunitz units/sample) 
for 15 min at room temperature to eliminate any genomic 
DNA contamination. The concentration of purified RNA was 
quantified using a NanoDrop™ (NanoDrop Technologies) 
45 
and 1 µg of total RNA was used to synthesize cDNA tem-
plates by oligo(dT) priming using the Superscript First-
Strand cDNA Synthesis System™. 
qRT-PCR was performed with the ABI Prism 7700 
Sequence Detection System (Applied Biosystems; 40 cycles; 
50 
melting for 15 sat 95° C.; annealing and extending for 60 sat 
60° C.) using SYBR Green DNA intercalating dye. Gene 
transcript concentration in the sample cDNA template solu-
tions was quantified by preparing a functional range of dilu-
tions from an absolute standard for each gene. Linear stan-
55 dard curves were then generated by plotting the log of the 
known concentration versus the Cr value (the cycle number at 
which the fluorescence reached a threshold level). Oligo-
nucleotide primers (Table 1) were designed using Primer 
Express™ software (Applied Biosystems). 
TABLE 1 
Accession Number Forward Primer Reverse Primer 
Runx 2/NM009820 5'-GGCCTTCAAGGTTGTAGCCC-3' 5'-CCCGGCCATGACGGTA-3' 
SEQ ID NO, 5 SEQ ID NO, 6 
US 8,445,006 B2 
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TABLE 1-continued 
Gene/Gen Bank 
Accession Number Forward Primer Reverse Primer 
OCN/X04141 5'ACGAGCTAGCGGACCACATT-3' 5'-CCCTAAACGGTGGTGCCATA-3' 
SEQ ID NO, 7 SEQ ID NO, 8 
BSP/J04215 5'-TGACGCTGGAAAGTTGGAGTT-3' 5'-GCCTTGCCCTCTGCATGTC-3' 
SEQ ID NO, 9 SEQ ID NO, 10 
Alkaline Phosphatase Biochemical Activity and Calcium 
Incorporation Assays 
ALP activity was quantified at 7 days in culture using a 
15 
modification of the Sodek and Berkman method. Briefly, cells 
were rinsed with PBS and scraped in cold 50 mM Tris-HCI. 
After sonication and centrifugation, the protein concentration 
was quantified using a Pierce Micro BCA protein assay kit. 
Equal amounts of protein (2.5 µg) were added to 60 µg/ml 20 
4-methyl-umbelliferyl-phosphate fluorescent substrate in 
diethanolamine buffer (pH 9.5). After a 60 min incubation at 
37° C., the fluorescence was read at an excitation of360 nm 
and an emission of 465 nm on an HTS 7000 Plus BioAssay 
Reader (Perkin Elmer). Enzymatic activity was standardized 25 
using purified calf intestinal alkaline phosphatase. 
Calcium content was determined by dissolving mineral-
ized deposits with 1 N acetic acid overnight. Appropriately 
diluted sample (25 µl) was added to 300 µl of arsenazo III-
containing Calcium Reagent (Diagnostic Services Ltd). The 30 
absorbance of the resulting samples was measured at 650 nm 
and compared to a linear standard curve of CaC12 in 1 N acetic 
acid. 
Tibial Implantation Procedure 
domized block design, in which the three conditions were 
randomized according to proximal/distal and left/right tibia 
placement, but were constrained into blocks containing one 
each of the conditions. A total ofl 2 animals with 16 implants 
per condition were used-seven for histology and nine for 
mechanical testing. One additional animal with one implant 
per condition was included as an extra in the event of tibia 
breakage during harvest or during the apparatus set-up for 
mechanical testing. 
Histomorphometry Analyses and Mechanical Testing 
Excised tibiae were fixed in 10% neutral buffered formalin 
for 1 week. The formalin-fixed tibiae were dehydrated in a 
graded series of alcohol incubations and then embedded in 
poly(methyl methacrylate). Ground sections of 50-80 µm 
were generated using the Exakt Grinding System™. Two 
longitudinal ground sections were generated per tibia, each 
containing two titanium plugs inserted transverse to the tib-
ia's long axis. Sections were then stained with Sanderson's 
Rapid Bone Stain™ and a van Gieson counter stain. Bone 
implant contact (BIC) was measured as the percentage of 
implant's circumference that was in direct contact with bone 
tissue (Adobe Photoshop® CS imaging software). 
Implant mechanical fixation to the bone was measured 
with a pull-out force test using a biomechanical testing appa-
ratus (EnduraTEC Bose ELF 3200). The ends of each excised 
tibia were secured in a custom designed holding apparatus 
with the exposed head of each implant facing in the direction 
Commercially pure titanium implants (FIG. 4) were soni- 35 
cated in de-ionized water for 20 min to remove surface debris. 
Implants were then dipped in 4% HF for 30 sec to remove the 
existing oxide layer and then incubated in 35% HN03 for 30 
min at 50° C. to regenerate a new oxide coating. Samples were 
transferred to 1.8 N NaOH for 1 min to terminate the oxida-
tion reaction. Implants were then rinsed and boiled in de-
ionized water for 1 h. To create the bioactive coating, the 
implants were incubated in 20 µg/ml GFOGER peptide (SEQ 
40 of the pull motion and centered along the axis of motion. A 
0.014" diameter piano wire was threaded through the implant 
head and both wire ends attached firmly to an 11 lb. INTER-
FACE load cell. Samples were pre-loaded with 2 N to ensure 
proper and identical wire tautness among implants. Tests ID NO: 1) or type I collagen solution for 1 h. Control titanium 
rods were incubated in PBS. 45 were performed at a constant force rate of 0.2 N/sec using 
WINTEST application software. The direction of the pull was 
parallel to the long axis of the implant. The pull-out force (N) 
was the maximum load achieved before failure and was deter-
Implantations were conducted in accordance with an 
IACUC-approved protocol. Both hind legs of anesthetized, 
mature Sprague-Dawley male rats (250-350 g) were shaved 
and scrubbed with alcohol. The medial aspect of the proximal 
tibial metaphysis was exposed through an antero-medial skin 50 
incision, leaving the medial collateral ligament intact. Using 
a saline-cooled drill, two defects were created in each tibia. 
Sterile implant rods were press fit into the defects. Periosteum 
was mobilized and sutured over the implantation site, and the 
skin was closed with wound clips. Subjects were euthanized 55 
after 4 weeks and proximal tibiae were fixed in neutral buff-
ered formalin for histology or recovered without fixation and 
maintained in PBS-moistened gauze for immediate mechani-
cal testing. 
Based on power calculations and previous reports in the 60 
literature, it was estimated that a minimum of eight implants 
per experimental group are required to detect differences of 
10% in mechanical testing and a minimum of four implants 
per experimental group are required for histomorphometry 
for a total of 11 implants per experimental group. In this 65 
model, each animal receives four implants, two in each tibia. 
The sample conditions were distributed according to a ran-
mined from the recorded load vs. displacement data. 
Recombinant FNIII7 _10 Production 
A mono biotinylated FN fragment spanning the 7-10th type 
III repeats of FN, FNIII7 _10, was produced using standard 
recombinant DNA techniques. cDNA encoding for human 
FNIII7 _10 was ligated into the XA3 plasmid (Pinpoint System, 
Promega). See for example, S. M Cutler and A. J Garcia. 
(2003) Engineering cell adhesive surfaces that direct intergin 
alpha5betal binding using a recombinant fragment of 
fibronectin, Biomaterials, 24: 1759-70. The resulting con-
struct, encoding for FNIII7 _10, with a biotin tagging sequence 
at the amine terminus, was amplified in DH5a cells, purified, 
and sequenced. JM! 09 bacterial cells were transformed with 
the plasmid and streaked onto LB agar plates containing 100 
µg/ml ampicillin and incubated overnight. Colonies were iso-
lated and dynamically cultured in LB broth (100 µg/ml ampi-
cillin; 2 µm d-biotin). At 6 h, 100 µM IPTG was added to 
augment protein production. The cell broth was spun down at 
8000 g for 10 min at 4 ° C., and the cell pellet was resuspended 
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at 10 ml/g of cell paste in lysis buffer (50 mM Tris-HCI pH 
7.5, 50 mM NaCl, 5% glycerol). Lysozyme (1 mg/ml) was 
added at 4 ° C. to the cell suspension and stirred for 20 min, 
then sodium deoxycholate (1 mg/ml) for 5 min, and finally 
DNase I (40 µg/ml) for another 10 min. The lysate was cen- 5 
trifuged (10,000 g) for 20 min. The protein supernatant was 
sterile-filtered, and purified by affinity chromatography using 
14 
flow rate of 15 µI/min in DPBS. Ligands were tethered by 
activating the surface with NHS/EDC for 10 min at a 10 
µI/min flow rate, and ligand solutions were subsequently 
injected at a flow rate of 4 µI/min for 30 min. Finally, surfaces 
were washed with 20 mM glycine at 10 µI/min and the signal 
was allowed to stabilize for 2 min thereafter to measure 
tethered peptide levels. To assay for the relative degree of 
biotinylation, a solution of FNIII7 _10 was flowed over a 
streptavidin chip at 20 µI/min for 4 min. Resonance units 
a 5 ml column ofU!tralink Immobilized Monomeric Avidin 
(Pierce) connected to a gradient pump, UV monitor, and 
fraction collector (BioRad, Hercules, Calif.). Briefly, after 
sequential column washes with regeneration and elution buff-
ers, the protein solution was allowed to bind to the column for 
10 (RU) were converted to surface density values (10 RU=l 
ng/cm2). 
Centrifugation Cell Adhesion Assay 
A modification of a centrifugation assay was used to apply 
controlled detachment forces to cells adhering to engineered 
1 h at a 0.4 ml/min flow rate. After washing with DPBS, 
elution buffer (0.5 mg/ml d-biotin in DPBS) was flowed 
through (1 ml/min) and the eluted fractions monitored for 
protein. Protein fractions were filtered using 30 kDa Micro-
con centrifugal filter devices (Millipore, Bedford, Mass.) to 
remove d-biotin, and verified as >98% pure FNIII7 _10 by 
Western blotting. Purified samples were flash frozen for stor-
age (-80° C.). 
15 surfaces. Multi-wells of engineered surfaces were created on 
gold-coated polystyrene plate lids using silicone gaskets 
(Grace Bio-Labs, Bend, Oreg.). Mixed SAMs were 
assembled and ligands tethered at varying densities. MC3T3-
El cells were labeled with 4 mM calcein-AM, a membrane-
Model Biomaterial Surfaces 
Self-assembled monolayers (SAMs) of alkanethiols on 
gold were used to present well-defined, ordered surfaces with 
anchoring groups within a non-fouling background. Tri( eth-
ylene glycol)-terminated alkanethiol (HS-(CH2) 11 -
(0CH2CH2)3---0H; EG3) and carboxylic acid-terminated 
alkanethiol (HS-(CH2) 11-(0CH2CH2)6---0CH2COOH; 
EG 6 -COOH) were previously synthesized and characterized. 
Gold-coated substrates were prepared by sequential deposi-
tion of titanium (lOOA) andgold(200 A) films via an electron 
beam evaporator (Thermionics Laboratories, Hayward, 
Calif., 2xl o-6 Torr, 1 A/s) onto clean 6-well plate lids or glass 
coverslips. Mixed SAM surfaces were prepared on substrates 
20 permeable green fluorescent dye, in 2 mM dextrose-DPBS for 
30 min and resuspended in a-MEM with 10% FBS. Cells 
were seeded onto the surfaces at 200 cells/mm2, and allowed 
to attach for 1hat37° C. For blocking antibody experiments, 
cells were incubated in the presence of function-perturbing 
25 antibodies (10 µg/ml) for 10 min with gentle agitation prior to 
cell seeding. Before centrifugation, cell images were taken 
using a Nikon TE-300 fluorescence microscope and Spot RT 
digital camera. Wells were then filled completely with dex-
trose-PBS, sealed, inverted, and centrifuged for 5 min at a 
30 prescribed speed on a Beckman Allegra 6 centrifuge (GH 3.8 
rotor) to apply normal detachment forces. Media was then 
gently aspirated from the wells, and wells were refilled for 
post-spin image collection. Post/pre-spin cell ratios were 
determined by image analysis, and this adhesive fraction was by immersing in a 1.0 mM mixed solution of EG3/EGc 
COOH thiols ( 4 h). Peptide ligands were tethered using stan-
dard peptide chemistry. Briefly, following washing in ethanol 
and ultrapure H20, SAMs were incubated in 2.0 mM EDC 
and 5 .0 mM NHS in 0.1 M 2-(N-morpho )-ethanesulfonic acid 
and 0.5 M NaCl (pH 6.0), and subsequently immersed in a 20 
mM solution of 2-mercaptoethanol in deionized H20. Adhe- 40 
sive ligands in PBS were then incubated on the activated 
supports for 30 min and the unreacted surface NHS esters 
were then quenched in 20 mM glycine. Finally, the surfaces 
were blocked in 1 % heat-denatured bovine serum albumin 
(BSA) and then incubated overnight in DPBS to reduce non- 45 
specific protein adsorption. 
35 plotted against ligand surface density to obtain cell adhesion 
profiles. 
ELISA and Surface Density Measurements 
An ELISA was used to probe for the biological activity of 
the FNIII7 _10 fragment compared to pFN. FNIII7 _10 or pFN 
was adsorbed onto either uncoated or Neutravidin-coated 50 
(100 µg/ml) 96-well black U-well Dynex plates at various 
concentrations for 30 min. Following incubation in blocking 
buffer (0.25% BSA, 0.1 M EDTA, 2.5% Tween-20, 
0.00125% NaN3), HFN7.1 antibody (0.6 µg/ml in blocking 
buffer) was added for 1 hat 37° C., and, after washing with 55 
blocking buffer, surfaces were incubated in alkaline phos-
phatase-conjugated anti-mouse IgG (0.6 µg/ml) for 1hat37° 
C. Washed surfaces were exposed to 4-methylumbelliferyl 
phosphate (25 mg/ml in 10 mM diethanolamine, pH 9.5). The 
resulting fluorescence was quantified using an HTS 7000 Plus 60 
plate reader (Perkin Elmer, Foster City, Calif.) at 360 nm 
excitation and 465 nm emission. 
Immunofluorescence Staining for Integrins and Focal Adhe-
s10ns 
Surfaces were prepared on either 6-well plate lids or 35 mm 
tissue culture dishes, and cells seeded at 75 cells/mm2 in 
serum-containing media for 4 hat 37° C. For integrin stain-
ing, a cross-linking/extraction biochemical method that 
selectively isolates bound integrins was employed. Cells were 
washed, and 1.0 mM DTSSP (Pierce) was added for 15 min to 
cross-link ligated integrins. After quenching with 50 mM 
Tris, uncrosslinked cellular components were extracted in 
0.1 % SDS supplemented with protease inhibitors (350 µg/ml 
PMSF). Samples were then blocked in 5% FBS for 1 h and 
incubated with integrin-specific antibodies for 1 hat 37° C. 
Fluorochrome-labeled secondary antibodies were then incu-
bated for 1 h at 37° C. Following washing, samples were 
mounted on slides with Gel/Mount mounting media 
(Biomeda, Foster City, Calif.). For staining of focal adhe-
sions, cells were extracted in 0.5% Triton X-100 in ice-cold 
cytoskeleton buffer (50 mM NaCl, 3 mM MgCl2, 150 mM 
sucrose, 20 µg/ml aprotonin, 1 µg/ml leupeptin, 1 mM PMSF, 
50 mM Tris, pH 6.8) for 2 min and fixed in cold 3.7% form-
aldehyde in DPBS for 5 min. Cultures were blocked, subse-
quently incubated in anti-vinculin monoclonal antibody 
(1 :70 in 5% FBS) and fluorochrome-labeled secondary anti-
bodies for 1 h, and samples mounted on slides. 
FAK Phosphorylation 
Surface density measurements were obtained via surface 
plasmonresonance (SPR) using a Biacore X instrument (Bia-
core, Piscataway, N.J.). Mixed SAM surfaces were prepared 
as described above onAu-coated SIA chips (Biacore ), primed 
with sterile DPBS, and the baseline allowed to stabilize at a 
Cells were detached and gently agitated in serum-free sus-
pension for 45 min to reduce background. Cells were then 
65 seeded at 200 cells/mm2 serum-free for 1 h. Cells were lysed 
in RIPA buffer (1%TritonX-100,1 % sodium deoxycholate, 
0.1 % SDS, 150 mM NaCl, 150 mM Tris-HCI (pH 7.2), 350 
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µg/ml PMSF, 10 µg/ml leupeptin, and 10 µg/ml aprotonin) for 
20 min on ice. Samples were pipetted up and down 20 times 
and centrifuged at 8000 g for 10 min to shear DNA and isolate 
protein contents. Total protein was quantified using micro-
BCA (Pierce). Equal amounts of protein were boiled for 10 5 
min in Laemmli buffer and separated by SDS-PAGE on a 7% 
gel, transferred to nitrocellulose membranes, and blocked 
with Blotto (5% nonfat dry milk, 0.20% Tween-20) overnight 
were adsorbed GFOGER peptide (SEQ ID NO: 1) on Ti, 
adsorbed linear RGD peptide (SEQ ID N0:3 ), adsorbed fetal 
bovine serum (10% in PBS), and non-adhesive blocked Ti. 
Cells were seeded without antibody or in the presence of 
either anti-a2 or anti-av integrin blocking antibodies. 
ANOVA: p<lE-9; *GFOGER peptide (SEQ ID NO:l) w/o 
Ab>GFOGER peptide (SEQ ID NO:l) with anti-a2 (p<6E-
6); #serum w/o Ab>serum with anti-av (p<6E-6). 
at 4 ° C. Membranes were gently rocked in antibodies against 
FAK and specific phosphorylated FAK tyrosine residues 10 
(anti-total FAK at 1 µg/ml, anti-PAK pY397 at 0.35 µg/ml, 
anti-PAK pY576 at 0.5 µg/ml) for 1 h. After washing with 
TBS-Tween (20 mM Tris HCl pH 7.6, 137 mM NaCl, 0.1 % 
Tween-20), secondary antibody (biotin-conjugated anti-rab-
Cell adhesion to the RGD-treated surface was equivalent to 
background levels observed on titanium blocked with non-
adhesive proteins, reflecting the inability of this short peptide 
to passively adsorb onto titanium. Importantly, a blocking 
anti-a2 antibody completely eliminated cell adhesion to 
GFOGER peptide-treated (SEQ ID NO: 1) surfaces, verifying 
bit IgG; 1 :20,000) was added for 1 h, followed by alkaline 15 
phosphatase-conjugated anti-biotin antibody (1:10,000) in 
Blotto. Immunoreactivity was assessed by ECF fluorescent 
substrate. FAK bands were visualized by a Fuji Image Ana-
lyzer and phosphorylation levels normalized to total FAK. 
the peptide's specificity for the a2~ 1 integrin. However, this 
a2~ 1 antibody had no effect on adhesion to serum-exposed 
titanium, demonstrating that stromal cell adhesion to 
untreated titanium is not mediated by a2~ 1 integrin. Since 
untreated titanium adsorbs abundant RGD-containing serum 
Cell Proliferation Rate 
Cells were seeded on surfaces in 10% serum for 16 h, and 
BrdU (3.1 µg/ml) was added for the last 4 h. After washing 
with DPBS, samples were fixed in 70% cold ethanol for 10 
min, denatured in 4 M HCl for 20 min, neutralized in 50 mM 
NaCl in 100 mM Tris-HCI (pH 7.4), washed, and blocked 
with 5% FBS+ 1 % heat-denatured BSA. Cultures were incu-
bated in anti-BrdU antibody (1: 1000) and AlexaFluor488-
conjugated anti-mouse IgG (1:200). Nuclei were counter-
stained with Hoechst dye (1:10,000). Fluorescent images 
were used to quantify the number of cells positive for BrdU 
relative to total cell nuclei using an in-house image analysis 
routine. Ten representative fields were analyzed per well with 
multiple wells for each surface condition. 
Statistics 
20 proteins, such as vitronectin, adhesion to these surfaces most 
likely involves the av~3 integrin, which recognizes RGD in a 
wide variety of proteins and synthetic peptides. Indeed, a 
function-perturbing anti-av antibody had no effect on adhe-
sion to the GFOGER peptide (SEQ ID NO: 1) but completely 
25 blocked adhesion above background on the serum-exposed 
titanium. These results demonstrate that the bioactive 
GFOGER peptide (SEQ ID NO: 1) specifically targets the 
a2~ 1 integrin. These adhesion results also show that untreated 
titanium surfaces, which directly adsorb serum proteins, pref-
30 erentially engage the av~3 integrin. Because GFOGER pep-
tide (SEQ ID NO: 1 )-coated and control titanium surfaces 
each interact with unique integrins, these surfaces may recruit 
different cell populations at the implant site and/or have 
diverse effects on cellular maturation and bone formation in 
35 VIVO. Data are reported as mean±standard error. Results were 
analyzed by one-way ANOVA using SYSTAT 8.0 (SPSS). If 
treatment level differences were determined to be significant, 
pair-wise comparisons were performed using a Tukey post-
hoc test. A 95% confidence level was considered significant. 
All of the in vitro assays were performed as two separate 40 
experiments in triplicate. 
EXAMPLE2 
Bioactive GFOGER-Peptide (SEQ ID NO:l) Surface 
Triggers The Transcriptional Machinery Necessary 
For Osteoblastic Differentiation 
EXAMPLE 1 
The Bioactive GFOGER (SEQ ID NO: 1) Peptide 
Specifically Targets The a2 ~ 1 Integrin 
To reproduce titanium implant surfaces in vitro, culture 
dishes were coated with a 300 A titanium layer via electron 
beam evaporation. The GFOGER peptide (SEQ ID NO: 1) 
was then passively adsorbed onto the titanium at a concentra-
tion of20 µg/ml, creating the integrin-targeted bioactive coat-
ing. Surface plasmon resonance spectroscopy revealed a sur-
face density of 123.2±6.2 ng/cm2 . Primary rat bone marrow 
stromal cells were used to validate this surface treatment 
strategy in vitro since this heterogeneous population contains 
osteoprogenitors and human bone marrow stromal cells are 
currently used in clinical applications. A centrifugation cell 
adhesion assay demonstrated greater stromal cell adhesion on 
the GFOGER-peptide (SEQ ID NO:l) surfaces compared to 
titanium surfaces pre-exposed to linear RGD peptide (SEQ 
ID N0:3) or serum (FIG. 1). 
FIG. 1 shows cell adhesion is greater on adsorbed 
GFOGER peptide (SEQ ID NO: 1) surfaces than untreated 
titanium (Ti) and is specific for the a2~ 1 integrin. The data 
represent 1 h serum-free bone marrow stromal cell adhesion 
and subsequent centrifugation at 12 g for 5 min. Surfaces 
To investigate the osteoblastic differentiation potential of 
these surfaces, quantitative RT-PCR (qRT-PCR) was used to 
45 probe osteoblast-specific gene expression in 7 day cultures of 
bone marrow stromal cells (FI GS. 2A-2C). The data represent 
osteoblast-specific gene expression measured by qRT-PCR 
for Runx2 transcription factor (FIG. 2A), osteocalcin (OCN) 
(FIG. 2B), and bone sialoprotein (BSP) (FIG. 2C) in rat bone 
50 marrow stromal cells cultured for 7 days on GFOGER peptide 
(SEQ ID NO:l) surfaces or untreated Ti. Runx2 ANOVA: 
*GFOGER peptide (SEQ ID NO:l)>Ti (p<0.02); OCN 
ANOVA: *GFOGER peptide (SEQ ID NO:l)>Ti (p<0.002); 
BSP ANOVA: *GFOGER peptide (SEQ ID NO:l)>Ti 
55 (p<0.05). 
Expression levels of Runx2/Cbfal, a transcription factor 
essential for bone formation and osteoblastic differentiation, 
were elevated on the GFOGER peptide (SEQ ID NO: 1 )-
treated surfaces compared to untreated titanium (FIG. 2A). 
60 The upregulation of this key osteoblast-specific transcription 
factor demonstrates the ability of the bioactive GFOGER-
peptide (SEQ ID NO: 1) surface to trigger the transcriptional 
machinery necessary for osteoblastic differentiation (FIG. 
2B). To determine whether this pattern of increased Runx2 
65 gene expression parallels similar increases in the expression 
of other osteoblast-specific genes, the transcript levels of 
osteocalcin and bone sialoprotein were also examined. For 
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both bone-specific markers, qRT-PCR revealed greater levels 
of gene expression on the GFOGER-peptide (SEQ ID NO: 1) 
surfaces compared with untreated titanium (FIGS. 2A-2C). 
These results indicate that the a2 ~ 1 integrin-targeted peptide 
promotes the expression of multiple genes specifically as so- 5 
ciated with a mature osteoblastic phenotype. 
Osteoblastic differentiation is also characterized by the 
activation of multiple proteins, including alkaline phos-
phatase (ALP). The ALP enzyme is often used as a marker for 
osteoblastic metabolic activity and an early indicator of 10 
osteoblastic differentiation. An ALP biochemical assay 
revealed elevated levels of activation on the GFOGER-pep-
tide (SEQ ID NO: 1) coating compared to untreated titanium 
(FIG. 3A). Because ALP is the enzyme responsible for hydro-
lyzing phosphate esters and inducing bone mineralization, 15 
these results suggest that this bioactive surface treatment may 
also be capable of promoting enhanced bone matrix mineral-
ization. ALP ANOVA: *GFOGER peptide (SEQ ID NO:l) 
>Ti (p<0.02). 
Matrix mineralization was examined as an in vitro end- 20 
point indicator of the osteoblastic phenotype in the bone 
marrow stromal cells. Calcium phosphate mineral deposition 
was examined after 14 days in culture using calcium content 
analysis. Cultures on GFOGER peptide-treated (SEQ ID 
NO:l) surfaces displayed a three-fold enhancement in cal- 25 
cium-based mineral deposition compared to untreated tita-
nium (FIG. 3B). Ca+2 ANOVA: *GFOGER peptide (SEQ ID 
NO: 1 )>Ti (p<2E-4). This enhanced capacity for mineraliza-
tion on the peptide-treated surfaces is in excellent agreement 
with the observed up-regulation in osteoblast-specific gene 30 
expression and ALP activity. These results verify the advan-
tageous effects of controlled a2 ~ 1 integrin-binding on cell 
function, in this case osteoblastic differentiation and matrix 
mineralization. 
18 
isolated patches along the surface of the implants. Image 
quantification to determine the percentage of the bone-im-
plant apposition (bone implant contact, BIC) demonstrated a 
nearly two-fold enhancement in bone apposition on the 
GFOGER peptide (SEQ ID NO: 1 )-coated surfaces compared 
to untreated titanium (FIG. SA). Bone apposition is measured 
as the percentage of implant's circumference that is in direct 
contact with bone mineral in the histological sections. 
ANOVA: p<4E-6, *GFOGER peptide (SEQ ID NO:l)>Ti 
(p<0.002), tGFOGER peptide (SEQ ID NO:l)>COL 
(p<0.01), #COL> Ti (p<0.04). 
Pull-out mechanical testing indicated significantly higher 
mechanical fixation of the peptide-functionalized implants 
compared to type I collagen or untreated titanium (FIG. SB). 
Osseointegration is measured as the maximum force [NJ nec-
essary to dislodge the implant in a pull-out test. ANOVA: 
p<9E-7, *GFOGER peptide (SEQ ID NO: 1 )>Ti (p<0.0009), 
tGFOGER peptide (SEQ ID NO:l)>COL (p<0.01). 
These results demonstrate a greater quantity and continuity 
of peri-implant bone mineral on the integrin-targeted 
GFOGER peptide (SEQ ID NO: 1) surfaces in vivo as well as 
enhanced mechanical integrity and osseointegration. In addi-
tion, the biomimetic peptide induced greater bone formation 
and apposition than the native ECM protein coating, demon-
strating the benefit of integrin-target mimetic peptides over 
whole biomolecules. 
This work proposes a specific biomolecular strategy to 
improve bone regeneration and osseointegration by exploit-
ing the cell adhesive activity of type I collagen, the most 
abundant matrix component in bone. In particular, type I 
collagen modulates intracellular signal transduction by bind-
ing to the a2 ~ 1 integrin, which enhances the expression of the 
osteoblastic phenotype. It also exhibits low immunogenicity 
and high conformational stability, making it extremely suit-
EXAMPLE3 
Integrin-Targeted GFOGER Peptide (SEQ ID NO:l) 
Surfaces Enhance In Vivo Osseointegration 
35 able for implantation. However, designing surface treatments 
using whole matrix molecules, such as type I collagen, is 
often limited by a lack of specificity for particular integrins 
and thus exhibit minimal control over cellular responses. In 
addition, native matrix proteins often have binding sites for 
To evaluate the performance of the bioactive GFOGER 
peptide (SEQ ID NO: 1) treatment in vivo, osseointegration in 
a rat tibia cortical bone model was quantified using quantita-
tive histomorphometry and pull-out mechanical testing. A 
cylindrical titanium implant rod with a tapered stop collar was 
designed (FIG. 4). The tapered head ensures that all implants 
are inserted into the bone at the same depth, guaranteeing 
uniform bone contact among treatments. Using a saline-
cooled drill, two defects 2 mm in diameter were created in the 
medial aspect of the proximal tibial metaphysis. Implant rods 
consisting of GFOGER peptide (SEQ ID NO: 1) functional-
ized or untreated (control) titanium were press fit into the 
cortical defects. After four weeks, the rat tibiae were har-
vested and evaluated for bone apposition by histological 
staining and mechanical integration by pull-out testing. His-
tological sections revealed substantial and contiguous bone 
mineral along the periphery of GFOGER peptide (SEQ ID 
NO: 1 )-treated titanium implants. Representative micro-
graphs show 50-80 µm longitudinal ground sections of rat 
tibia stained with Sanderson's Rapid Bone Stain™ and van 
Gieson counterstain. Cells stain dark to light blue, soft tissue 
elements stain blue-green, and bone matrix stains yellow 
orange to autunm orange. 
Less bone mineral was visible on surfaces treated with the 
40 other ligands, which may trigger antagonistic signaling cas-
cades that may ultimately interfere with desired cell func-
tions. The GFOGER peptide (SEQ ID NO:l) strategy 
described in this study targets the a2~ 1 integrin-ligand inter-
action that is crucial for the development and maintenance of 
45 the osteoblast phenotype as well as the mineralization of the 
extracellular matrix. In vitro assays using bone marrow stro-
mal cells verified that a GFOGER peptide (SEQ ID NO: 1) 
coating enhances expression of multiple osteoblast-specific 
genes and alkaline phosphatase activity when compared to 
50 untreated titanium controls. This bioactive treatment also 
improved calcification of the extracellular matrix, demon-
strating functional osteoblastic differentiation. Notably, the 
cortical bone implantation studies revealed greater bone tis-
sue formation on the surface of GFOGER peptide (SEQ ID 
55 NO: 1 )-treated titanium implants, in terms of both quantity 
and connectivity. Most significantly, it has been shown that 
the GFOGER peptide (SEQ ID NO: 1) coating improved the 
implant's mechanical fixation and functional osseointegra-
tion as determined by a quantitative pull-out test. Faster inte-
60 gration of these GFOGER peptide (SEQ ID NO: 1) coated 
implants would result in sooner and more reliable loading in 
a clinical setting, improving device function and patient out-
comes. Not only does this bioactive coating enhance bone 
native type I collagen, and the adjacent mineral appeared 65 
more porous. Significantly less mineral staining was present 
formation and implant integration, but it is also created using 
a single-step procedure conducted under physiological con-
ditions, thus eliminating the cytotoxicity and biocompatibil-
on untreated titanium and the mineral deposits appear in ity concerns associated with covalent immobilization meth-
US 8,445,006 B2 
19 20 
ods. As such, this GFOGER peptide (SEQ ID NO: 1) surface 
treatment represents a simple, clinically relevant approach to 
improving orthopaedic and dental titanium implant integra-
tion. Due to the fundamental character of receptor-ligand 
principles and the significance of cell-collagen interactions in 5 
multiple tissues, this material coating strategy may also have 
the potential to improve implant integration in non-ortho-
paedic tissue systems. For example, this implant coating tech-
nology can be applied to cardiovascular, skin, liver, and kid-
ney-related devices as the a2 ~ 1 integrin plays a central role in 10 
the function and repair of these tissues. 
solution ratios ranging from 0.0001 to 0.1 via ELISA (data 
not shown). An EG6 -COOH:EG3 solution ratio of0.02 was 
determined to yield the highest tethered ligand density while 
maintaining background levels of non-specific adsorption. 
This model system presents a well-defined surface with a 
single adhesive ligand that allows direct functional compari-
son on a molar basis among different adhesive ligands. 
Three adhesive ligands were examined: (i) "RGD peptide" 
(GRGDSPC) (SEQ ID N0:3); (ii) "RGD-PHSRN peptide" 
(GRGDG13PHSRN) (SEQ ID N0:4) presenting the RGD 
and PHSRN (SEQ ID NO: 11) motifs joined by a polyglycine 
sequence designed to mimic the spacing of the domains in FN 
EXAMPLE4 
Recombinant FNIII7 _10 Has Equivalent Biological 
Activity As Plasma FN 
A recombinant FN fragment (FNIII7 _10), presenting both 
the RGD and the synergy PHSRN (SEQ ID NO: 11) domain in 
the correct native structure and orientation has previously 
been developed in order to target the a 5 ~ 1 integrin. Recom-
binant DNA technology allows for production ofFN-mimetic 
ligands that reconstitute the secondary structure of the native 
ligand and affords the ability to engineer enhanced or new 
functionality. A monobiotinylated FNIII7 _10 has been pro-
duced by encoding a biotinylation sequence at the amine 
terminus of the protein. This FN fragment represents an 
enhanced version of the previously described fragment with a 
single biotin tag introduced at a specific site. In addition to 
providing a simple system to generate large quantities of 
purified protein via affinity chromatography (2-10 mg from 1 
L culture, >98% purity), this strategy incorporates a well-
defined tag for tethering onto avidin supports as well as a 
tracking marker for future in vitro and in vivo studies. The 
biological activity of FNIII7 _10 was evaluated ELISA using 
the HFN7.1 monoclonal antibody, which is specific for the 
central cell-binding domain in the 9-lO'h type III repeats of 
FN. Furthermore, it has been shown that HFN7.1 binding 
efficiency correlates closely with the binding affinity of the 
integrin a5 ~ 1 for FN. For passively adsorbed ligands, HFN7 .1 
binding increased with protein coating concentration for both 
pFN and FNIII7 _10 , and there were no significant differences 
but not interfere with the adhesion characteristics of the two 
linked sequences; and (iii) FNIII7 _10. Quantification ofligand 
tethering onto SAMs was conducted via SPR. Tethered ligand 
15 surface density increased hyperbolically with coating con-
centration, reaching saturation levels at higher concentrations 
(FIG. 7). The measured surface densities are in good agree-
ment with previous results, and are below the theoretical 
limits based on the calculated surface density of the EG6 -
20 COOH thiols. Although these surfaces were prepared in situ 
in the SPR, as opposed to the surfaces prepared on the bench-
top used for the cell culture work, ELISA-based measure-
ments indicated no significant differences in tethered profile 
shape or relative densities (data not shown), supporting the 
25 validity of these quantitative density values. This data indi-
cates that control over tethered peptide density can be 
achieved by varying coating concentration accordingly. 
Although the tethering curves exhibited similar hyperbolic 
profiles, RGD peptide (SEQ ID N0:3) and RGD-PHSRN 
30 (SEQ ID N0:4) tethered at > 10-fold higher molar densities 
than FNIII7 _10 (FIG. 7). Tethering efficiencies for RGD pep-
tide (SEQ ID N0:3) and RGD-PHSRN (SEQ ID N0:4) were 
identical. Tethered ligands were biologically active as deter-
mined by cell spreading. At saturated surface densities, all 
35 engineered surfaces exhibited equivalent levels of cell 
spreading, while very few cells attached to EG 3 or unactivated 
EGcCOOH: EG3 surfaces (data not shown). 
To further characterize the adhesive activities of these engi-
neered biointerfaces, the adhesion strength of MC3T3-El 
40 cells was measured using a centrifugation assay that applies 
controlled detachment forces to adherent cells. For all sur-
in either the hyperbolic shape or magnitude for the binding 
curves (FIG. 6A), indicating equivalent functional activity 
between monobiotinylated FNIII7 _10 and pFN. To demon- 45 
strate biotinylation of the fragment, both ELISA on Neutra-
vidin-coated polystyrene and SPR on streptavidin-coated 
gold chips (FIG. 6B) were performed. High levels ofHFN7.1 
antibody bound to FNIII7 _10 incubated on N eutravidin-coated 
surfaces, whereas background levels ofHFN7 .1 binding were 50 
observed on Neutravidin supports exposed to pFN (no biotin 
tag). 
faces, the fraction of adherent cells increased sigmoidally 
with adhesive ligand surface density (FIG. 8), and adhesion 
strength was characterized as the ligand density required for 
half-maximal adhesion (ADH50). Adhesion strength is 
inversely related to ADHs0 , as a shift of the curve left (de-
creasing ADH50) represents an increase in adhesion strength 
since less ligand is needed for cell adhesion. Cell adhesion 
profiles for RGD peptide (SEQ ID N0:3) and RGD-PHSRN-
tethered (SEQ ID N0:4) surfaces were almost identical, and 
ADH50 values were 2300 and 1950 fmol/cm2 , respectively, 
indicating similar adhesive activity for these two peptides 
(FIG. 8). FNIII7 _10-tethered surfaces displayed a pronounced 
leftward shifted adhesion profile compared to the other two 
Similarly, SPR measurements revealed high levels of 
immobilized FNIII7 _10 on strepavidin-coated chips. 
EXAMPLES 
FNIII7 _10 Displays Enhanced Cell Adhesive Activity 
Compared to RGD Peptides 
55 peptide tethered-surfaces, reflected in the relatively low 
ADH50 value of 70 fmol/cm2 (FIG. 8). These data indicate 
that the FNIII7 _10 tethered surface displays higher cell adhe-
sive activity compared to RGD peptide (SEQ ID N0:3) or 
RGD-PHSRN (SEQ ID N0:4)-tethered surfaces. 
60 
Mixed alkanethiol SAMs were used as model surfaces 
presenting well-defined anchoring groups (-COOH) for 
controlled tethering of ligands in a protein adsorption resis-
tant background ( tri( ethylene glycol groups): EG 3 ). Peptides 
were tethered via free amines using NHS/EDC coupling 65 
chemistry. FNIII7 _10 tethering/adsorption onto activated/un-
activated SAMs with EGcCOOH:EG3 has been examined in 
EXAMPLE 6 
FNIII7 _10 Surfaces Display Different Integrin 
Specificity Than RGD-Functionalized Supports 
These different adhesive surfaces were examined to deter-
mine if they supported cell adhesion by binding different 
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integrin receptors. Function-perturbing antibodies directed 
against different integrin subunits were used to block adhe-
sion to the engineered interfaces. Since integrins a5 ~ 1 and 
av~3 represent the dominant adhesion receptors for FN in 
MC3T3-El cells, the contributions of these receptors to adhe- 5 
sion strength on the peptide-functionalized SAMs was exam-
ined. Surfaces were tethered with maximum density of 
ligand, and the relative cell adhesion was normalized to 
unblocked controls. Blocking antibodies directed against 
a5 ~ 1 integrin reduced adhesion to background levels (EG3 ) 10 
for the FNIII7 _10 tethered surface, but only slightly reduced 
adhesion on the RGD peptide (SEQ ID N0:3) and RGD-
PHSRN (SEQ ID N0:4) surfaces (FIG. 9A). In contrast, 
antibodies against the ~3 integrin subunit did not alter adhe-
sion significantly for FNIII7 _10-tethered surfaces, but reduced 15 
adhesion over 7 5% for both the RGD peptide (SEQ ID N0:3) 
and RGD-PHSRN (SEQ ID N0:4) surfaces (FIG. 9A). These 
results demonstrate that the FNIII7 _10-tethered surface prima-
rily supports a5 ~ 1 -mediated adhesion; whereas, the RGD 
peptide (SEQ ID N0:3)- and RGD-PHSRN (SEQ ID N0:4)- 20 
functionalized surfaces promote av~3 -mediated cell adhe-
surface compared to the RGD-functionalized support (FIG. 
9B). The tyrosine-861, a major Src phosphorylation site, was 
phosphorylated at similar levels among both peptide-tethered 
surfaces (data not shown). These results demonstrate differ-
ential activation ofFAK on these engineered interfaces, sug-
gesting that different integrins trigger different signaling 
pathways on biomimetic surfaces. Because integrin-medi-
ated activation ofFAK has been linked to upregulation of cell 
proliferation, adhesion to the different biointerfaces was 
examined to determine if it would modulate MC3T3-El pro-
liferation. The proliferation rate of cells seeded for 16 h on 
each ligand-tethered surface was probed by BrdU incorpora-
tion. Cells seeded on FNIII7 _10-functionalized surfaces dis-
played a two-fold increase in cell proliferation rate compared 
to RGD-tethered surfaces at low and high relative peptide 
surface densities (FIG. 10). 
Well-defined biointerfaces are provided that present differ-
ent adhesive ligands to directly compare their biological 
activities in terms of cell adhesion strength, integrin binding, 
and signaling. Mixed SAMs ofCOOHEGc and EG3 -termi-
nated alkanethiols were optimized to engineer robust sup-
S!On. 
Since MC3T3-El cells assemble robust focal adhesions 
containing clustered integrins and intracellular structural and 
signaling proteins, integrin binding and focal adhesion 
assembly on the engineered interfaces was examined by 
staining for different integrin subunits and vinculin, which 
localizes to focal adhesions. MC3 T3-El cells were allowed to 
adhere on each saturated ligand-functionalized support for 4 
hand integrin binding was evaluated via a crosslinking/ex-
traction and immunostaining protocol, which isolates inte-
grins ligated to the ligand. Cells adhering to FNIII7 _10-teth-
ered surfaces displayed robust, well-defined adhesive 
structures containing a 5 ~ 1 integrins but minimal av~ 3 bind-
ing. Cells on RGD-tethered surfaces exhibited clustering of 
av~3 and little staining for a5 ~ 1 . The crosslinking and extrac-
tion technique relies in coupling free amines on both the 
receptor and ligand. Since the tethered RGD has no free 
amine, the av~3 staining in the RGD surfaces is attributed to 
focal adhesions that were not completely extracted. These 
results are further supported by the integrin antibody block-
ing adhesion data. Both surfaces assembled focal adhesions 
containing vinculin. These results further demonstrate that 
surfaces presenting FNIII7 _10 primarily support a5~ 1 -medi­
ated adhesion, while RGD functionalized SAMs mediate 
adhesion via av~3 . 
EXAMPLE 7 
FNIII7 _10 Interfaces Trigger Enhanced Signaling and 
Cell Proliferation Compared to RGD Surfaces 
The bioadhesive interfaces were examined to determine 
whether they modulate intracellular signaling and high-order 
cell activities. Levels ofFAK phosphorylation as a marker of 
integrin-mediated signaling were examined. FAK localizes to 
focal adhesions and activates various signaling cascades 
regulating cell survival, proliferation and differentiation. 
Phosphorylation of important tyrosine residues was probed 
for using site-specific antibodies in Western blotting. Phos-
phorylation oftyrosine-397, the autophosphorylation site on 
FAK which also binds to the p85 subunit of PB-kinase, was 
increased almost threefold on the FNIII7 _10 surface compared 
to the RGD-tethered surface at maximum peptide densities. 
Similarly, phosphorylation of tyrosine-576, located in the 
FAK catalytic loop and responsible for maximal FAK kinase 
activity, was significantly higher on the FNIII7 _10-tethered 
ports that present anchoring groups for ligand tethering 
within a non-fouling, protein adsorption-resistant back-
ground. Controlled bioadhesive interfaces were generated by 
25 tethering adhesive ligands via standard NHS/EDC chemistry, 
and the resulting tethered surface density could be easily 
modulated by altering the ligand concentration in solution 
during tethering. The ability to precisely control tethered 
ligand densities is an important design parameter as cell adhe-
30 sion, focal adhesion assembly, spreading and migration, neu-
rite extension, and cell differentiation exhibit peptide density-
dependent effects. The adhesive activities of three 
FN-mimetic ligands of increasing complexity were exam-
ined: (i) linear RGD peptide (SEQ ID N0:3) presenting the 
35 minimal cell adhesive motif ofFN; (ii) RGD-PHSRN peptide 
(SEQ ID N0:4) presenting the RGD and PHSRN (SEQ ID 
NO: 11) motifs joined by a polyglycine sequence designed to 
mimic the spacing of these domains in FN, and (iii) recom-
binant FNIII7 _10 reconstituting the primary and secondary 
40 structure of the central cell binding domain of FN. A linear 
RGD peptide (SEQ ID N0:3) was used in this study. Further-
more, current biomimetic surfaces mainly focus on linear 
RGD, making the use of linear RGD in this study more 
relevant to current strategies. On a molar basis, biointerfaces 
45 presenting FNIII7 _10 exhibited significantly higher adhesion 
strength, F AK activation, and cell proliferation rate than sup-
ports presenting RGD peptide (SEQ ID N0:3) or RGD-PH-
SRN (SEQ ID N0:4). Moreover, FNIII7 _10-functionalized 
surfaces displayed specificity for a5 ~ 1 integrin, while cell 
50 adhesion to SAMs presenting RGD peptide (SEQ ID N0:3) 
or RGD-PHSRN (SEQ ID N0:4) was primarily mediated by 
av~3 integrin. These results are significant to the rational 
engineering ofbioactive materials that promote cell adhesion 
and function. Importantly, recent evidence indicates that inte-
55 grin binding specificity, particularly a5 ~ 1 vs. av~3 regulates 
osteoblast and myoblast differentiation in response to bioma-
terial surface chemistry. Therefore, biomolecular engineering 
strategies that convey integrin binding specificity to bio-in-
spired materials may provide a facile route to elicit desired 
60 cellular responses. Finally, DNA recombinant technology 
provides a versatile platform to engineer bioactive ligands 
mimicking the structure of the native ligand as well as a 
system to incorporate new functionality. 
The improved adhesive activities of FNIII7 _10-engineered 
65 surfaces compared to RGD peptide (SEQ ID N0:3)- and 
RGD-PHSRN (SEQ ID N0:4) functionalized supports can be 
attributed to enhanced binding of integrin a5 ~ 1 . Simple RGD 
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linear peptides, even those co-presenting the PHSRN (SEQ 
ID NO: 11) motif in the appropriate spacing as in the native 
FN molecule, cannot support binding of integrin a5~u but 
instead promote binding of av~3 . The integrin specificity for 
a5 ~ 1 of FNIII7 _10-tethered surfaces is attributed to the pre- 5 
sentation of PHSRN (SEQ ID NO: 11) and RGD in the same 
structural context as the native FN ligand, while the RGD 
peptides either lack the PHSRN (SEQ ID NO: 11) site (RGD 
peptide, SEQ ID N0:3) or present it in a suboptimal orienta-
tion (RGD-PHSRN, SEQ ID N0:4). This result underscores 10 
the exquisite sensitivity of the integrin a5 ~ 1 -FN interaction 
on the specific molecular structure of the ligand. Notably, in 
addition to presenting PHSRN (SEQ ID NO: 11) and RGD in 
a specific structural conformation, FNIII7 _10 has the RGD 15 
motif constrained to a loop extending from the backbone of 
the molecule. While this RGD constrained conformation 
probably improves receptor binding affinity, the improved 
specificity ofFNIII7 _10 for a5 ~ 1 integrin cannot be attributed 
to the constrained RGD loop. The a5 ~ 1 -mediated enhance- 20 
ments in adhesion strength, FAK activation, and cell prolif-
eration rate on FNIII7 _10-engineered interfaces may reflect 
increases in the number ofintegrin-ligand bonds and/or a 5 ~ 1 -
specific activities. 
Surfaces presenting RGD-PHSRN (SEQ ID N0:4) exhib- 25 
ited identical adhesive activities as RGD-functionalized sup-
ports, suggesting that the PHSRN (SEQ ID NO: 11) motif in 
this peptide provides no additional effects. This result con-
trasts a previous study from Benoit and Anseth reporting 
enhanced activities of RGD-PHSRN (SEQ ID N0:4) com- 30 
pared to RGD peptide (SEQ ID N0:3) when presented within 
a hydro gel, although no antibody blocking experiments were 
performed. Possible explanations for this discrepancy include 
differences in peptide presentation/accessibility and cell 35 
type-specific activities. Furthermore, previous analyses with 
simple RGD peptide (SEQ ID N0:3) and PHSRN (SEQ ID 
NO: 11) peptide mixtures also documented increases in cell 
adhesion compared to pure RGD. It is important to point out 
that two of these studies employed peptide-amphiphile sup- 40 
ports, which exhibit significant peptide mobility. Reconfigu-
ration of the interface may allow for rearrangement ofligands 
24 
EXAMPLE 8 
Passively Adsorbed FNIII7 _10 Promotes Implant 
Osseointegration 
The ability of implant surfaces passively coated with 
FNIII7 _10 to promote bone formation in vivo and implant 
osseointegration was investigated. Titanium implants were 
coated with either FNIII7 _10 or plasma fibronectin (pFN) by 
incubating in 20 µg/ml solutions of the corresponding protein 
in PBS. Unmodified or protein-coated implants were 
implanted in the rat tibia as described above. After 4 weeks, 
implants were harvested and evaluated for bone-implant con-
tact and osseointegration. FNIII7 _10-coated implants 
enhanced bone-implant apposition compared to unmodified 
titanium or implants coated with the native ligand pFN (FIG. 
llA). More importantly, FNIII7 _10-coated implants signifi-
cantly increased mechanical fixation 3-fold compared to 
unmodified and pFN-coated titanium (FIG. llB). These 
results demonstrate that simple presentation of FNIII7 _10 on 
implant surfaces enhances bone formation and osseointegra-
tion compared to the current clinical standard (titanium) or 
implants coated with the native ligand pFN. The improved 
activity of FNIII7 _10 compared to pFN is attributed to the 
isolation of the bioactive, integrin-binding site of FN while 
excluding other domains that may have antagonistic effects. 
EXAMPLE 9 
Functionalized Titanium With Poly(OEGMA) 
Brushes 
A "grafting from" approach using surface-initiated atom-
transfer radical polymerization (SI-ATRP) of poly[ oligo( eth-
ylene glycol)methacrylate](poly(OEGMA)) brushes on tita-
nium (16) (FIG. 12A). Briefly, a 1:1 mixed self-assembled 
monolayer (SAM) of bromine-terminated initiator and unre-
active, methyl-terminated co-adsorbate was formed on a 
clean titanium surface. The terminal bromine served as the 
radical initiator for the subsequent SI-ATRP of oligo(ethyl-
ene glycol) monomer to form thick, dense poly(OEGMA) 
brushes. The hydroxyl groups at the termini of the oligo 
(ethylene glycol) side chains of poly(OEGMA) were con-
verted to 4-nitrophenyl carbonate by treatment with 4-nitro-
phenyl chloroformate (NPC) and functionalized with 
bioadhesive ligands via a urethane linkage. The progress of 
the synthesis was monitored by X-ray photoelectron spec-
to approximate the structural context in FN and "fit" the 
integrin. Moreover, these studies used extremely high surface 
densities of peptides (compared to physiological densities of 45 
FN) that could give rise to nonphysiological effects. Compre-
hensive analyses, including antibody blocking, varying pep-
tide surface densities, and signaling evaluations, are neces-
sary to fully establish the adhesive activities of these 
engineered surfaces. 
These data provide an experimental platform to engineer 
integrin-specific biointerfaces to manipulate cell and host 
responses to biotechnological/biomedical supports and 
implanted devices. Integrin binding specificity (a5 ~ 1 vs. 
av~3 ) may regulate cellular activities, including cell cycle 55 
progression and expression of differentiated phenotypes, as 
well as tissue healing responses. This approach of conveying 
integrin binding specificity may provide a robust biomolecu-
50 troscopy (XPS) and glancing angle Fourier transform infra-
red (FTIR) spectroscopy (FIG. 12A, 12B). 
lar strategy to elicit directed biological responses. In addition, 
integrin specific biomimetic surfaces utilizing recombinant 60 
peptides of matrix molecules, such as FNIII7 _10 , often exhibit 
lower immunogenicity and higher stability than the whole 
proteins, as well as lack binding sites for other ligands which 
may impede in a more directed cellular response. In particu-
lar, this surface strategy may present a clinically relevant 65 
approach to improving bone formation and integration in 
biomedical devices and tissue-engineered scaffolds. 
Two bioadhesive ligands with different integrin specifici-
ties were examined: (i) the recombinant fragment FNIII7 _10 , 
which presents the RGD motif in the 1 O'h type III repeat and 
the PHSRN (SEQ ID NO: 11) synergy sequence in the 9th type 
III repeat of FN in the correct structural context and exhibits 
high selectivity for integrin a5 ~ 1 ; and (ii) a linear RGD oli-
gopeptide (GRGDSPC) (SEQ ID N0:3) that primarily sup-
ports av~3-mediated adhesion and is considered the "gold" 
standard in the field. Controlled surface densities of tethered 
ligands were obtained by treating the NPC-modified polymer 
brushes with varying concentrations of peptide (FIG. 12C). 
The differences in tethering efficiency between FNIII7 _10 and 
RGD peptide (SEQ ID N0:3) can be attributed to significant 
differences in ligand size. Importantly, ligand densities 
adsorbed on control surfaces presenting unmodified poly 
(OEGMA) brushes were <5% of the density immobilized on 
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the functionalized surfaces, demonstrating the non-fouling 
nature of the urnnodified poly(OEGMA) brush. 
EXAMPLE 10 
26 
nium (p<0.01) (FIG. 13B). On the other hand, the RGD-
tethered brushes and serum-exposed titanium supported 
higher levels of bound avµ3 that the FNIII7 _10 support 
(p<O .006). These data demonstrate that FNIII7 _10-functional-
Assessment of In Vitro Bioresistance and Adhesive 
Capacity 
5 ized titanium selectively supports a5 ~ 1 -mediated cell adhe-
sion, whereas the RGD-tethered surface primarily binds av~3 
integrin. 
The in vitro bioresistance and adhesive capacity of 
unmodified poly(OEGMA) brushes and brushes with peptide 10 
tethered on titanium were assessed. Surfaces were incubated 
in serum-containing media for various times and subse-
quently challenged with osteoblastic cells for 1 h. In contrast 
to control urnnodified titanium which supported high levels of 
cell adhesion and spreading, urnnodified poly(OEGMA) 15 
brushes resisted cell adhesion for over 56 days. The unfunc-
tionalized poly(OEGMA) brushes exhibited excellent biore-
sistance compared to commonly-used self-assembled mono-
layers of tri( ethylene glycol)-functionalized alkanethiols on 
gold, which displayed loss ofbioresistance by the 10 day time 20 
point in serum-containing media. Moreover, poly(OEGMA) 
brushes presenting either FNIII7 _10 or RGD supported levels 
of cell adhesion comparable to the urnnodified titanium, dem-
onstrating that the tethered ligand is in a bioactive form that 
supports adhesive activities. Surface density dependent 25 
increases in available FNIII7 _10 ligand was demonstrated 
using a receptor-mimetic antibody-based assay (FIG. 12D). 
Taken together, these results demonstrate a robust approach 
to coat clinical-grade titanium with non-fouling/bioresistant 
oligo(ethylene glycol)-substituted polymer brushes which 30 
can be functionalized with controlled densities ofbioadhesive 
ligands. 
EXAMPLE 11 
EXAMPLE 12 
FAK Phosphorylation Assessment of Engineered 
Surfaces 
As a final demonstration of the integrin-specific nature of 
these engineered supports, FAK phosphorylation was 
assessed in the presence of integrin blocking antibodies. FAK 
is an intracellular signaling molecule involved in integrin-
mediated signal transduction and the osteogenic differentia-
tion pathway. Phosphotyrosine-specific antibodies were used 
to examine the activation state of three important tyro sines in 
FAK: Y397 (autophosphorylation site), Y576 (essential for 
maximal kinase activity), andY861 (major Src phosphoryla-
tion site) (FIG. 13C). FAK Y397 and Y576 exhibited higher 
phosphorylation levels on FNIII7 _10-engineered surfaces 
compared to RGD-functionalized brushes and serum-ex-
posed titanium (p<0.01 ), whereas Y861 phosphorylation was 
elevated for the RGD-functionalized and serum-exposed tita-
nium relative to the FNIII7-10-tethered surface (p<0.03). 
Moreover, blocking antibodies against a5, but not ~3, 
reduced the levels ofphospho-Y397 andY576 on the FNIII7 _ 
10-presenting titanium (p<O .04). For the RGD-functionalized 
poly(OEGMA) brushes, only the anti-~3 antibody reduced 
FAK phosphorylation (p<0.05). These differences in integrin 
In Vitro Evaluation of Engineered Titanium Surfaces 
35 binding specificity and FAK activation modulate cell signal-
ing pathways and higher order cellular activities. 
In vitro evaluation of these engineered titanium surfaces 
was performed using primary rat bone marrow stromal cells 
since this heterogeneous population contains osteoprogeni- 40 
tors, and human bone marrow stromal cells are currently used 
in clinical applications. Cell adhesion was examined using a 
centrifugation assay that applies a controlled detachment 
force. To allow direct comparisons between ligand-tethered 
surfaces, an equimolar ligand density of 0.9 pmol/cm2 was 45 
used; this value represents the highest ligand density that 
could be ascribed for both surfaces to be equimolar. Upon 
exposure to serum, high levels of cell adhesion were observed 
for polymer brushes modified with either FNIII7 _10 or RGD 
brushes, as well as unmodified titanium (which adsorbs 50 
RGD-containing adhesive proteins from serum) (FIG. 13A). 
Unmodified poly(OEGMA) brushes displayed background 
levels of adhesion, further illustrating the bioresistance of this 
system. Importantly, a blocking anti-a5 antibody completely 
eliminated cell adhesion to FNIII7 _10-tethered surfaces 55 
(p<0.005), whereas an anti-av antibody had no effect, verify-
ing the specificity of this surface for a5 ~ 1 integrin. Con-
versely, a function-perturbing anti-av antibody eliminated 
adhesion to both RGD-tethered surfaces and serum-exposed 
unmodified titanium (p<0.01) (FIG. 13A), indicating that 60 
adhesion to these surfaces is primarily mediated by the av~3 
integrin. As a complementary test of integrin specificity, inte-
grin binding was quantified using a biochemical cross-link-
ing/extraction/reversal technique. Consistent with the anti-
body blocking experiments, FNIII7 _10-tethered brushes 65 
supported significantly higher levels of bound a5 ~ 1 integrin 
compared to RGD-tethered brushes and serum-exposed tita-
EXAMPLE 13 
Assessment ofOsteoblastic Gene Expression of 
Engineered Surefaces 
Quantitative RT-PCR was used to probe osteoblastic gene 
expression in 7-day cultures of bone marrow stromal cells to 
investigate effects of integrin binding specificity on osteo-
blastic differentiation. Expression levels of Runx2/Cbfal, a 
transcription factor essential for osteoblastic differentiation 
and bone formation, were elevated on the FNIII7 _10-function-
alized surface compared to brushes functionalized with 
equimolar densities ofRGD (p<0.03) (FIGS. 14A-14C). The 
late osteoblastic markers osteocalcin (OCN) (FIG. 14B) and 
bone sialoprotein (BSP) (FIG. 14C) also exhibited increased 
transcript levels on FNIII7 _10-tethered brushes relative to 
RGD functionalized supports (p<0.003). Consistent with the 
gene expression results, FNIII7 _10-tethered surfaces dis-
played higher alkaline phosphatase activity than RGD-func-
tionalized surfaces (p<0.03) (FIG. 14D). Finally, matrix min-
eralization, as determined by calcium incorporation, was 
used as an end-point functional marker. FNIII7 _10-engineered 
titanium displayed a 2-fold enhancement in mineralization 
relative to the RGD-tethered supports (p<0.01) (FIG. 14E). 
No differences were observed between RGD-functionalized 
brushes and serum-exposed unmodified titanium for any dif-
ferentiation marker. Collectively, these results demonstrate 
that non-fouling brush surfaces presenting FNIII7 _10 to target 
a5 ~ 1 integrin trigger enhanced osteoblastic differentiation 
and mineralization in primary bone marrow stromal cells 
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compared to RGD-tethered brushes and serum-treated tita-
nium surfaces that support av~3binding. 
EXAMPLE 14 
28 
presentation of the linear RGD sequence has no effects on 
implant osseointegration. Unmodified titanium displayed 
higher fixation than the unfunctionalized poly(OEGMA) 
brush (p<0.01), but the pull-out force was not statistically 
Assessment of Osseointegration of Engineered 
Surfaces 
5 different from the RGD-tethered surface. Remarkably, 
FNIII7 _10-functionalized titanium exhibited higher mechani-
cal fixation than the unmodified titanium (p<0.05), indicating 
that this biomolecular engineering strategy outperforms the 
Osseointegration of implants in a rat tibia cortical bone 
model was quantified to evaluate the in vivo performance of 10 
the engineered titanium surfaces in bone healing. Impor-
tantly, this in vivo model provides a rigorous platform to 
evaluate implant coating function in a relevant orthopaedic 
setting. Two 2.0-mm diameter defects were drilled into the 
medial aspect of the proximal tibial metaphysis using a saline 
cooled drill. Tapered cylindrical implants (FIG. 4) of clinical-
grade titanium were press-fit into the cortical defects. 
Implants were machined with a tapered stop collar (401) to 
ensure equivalent initial bone contact across all samples, and 
each implant had a small channel ( 403) spanning the head to 
permit subsequent pull-out testing following explantation. 
Biomaterial surface treatments evaluated were (i) unmodified 
poly(OEGMA) brushes, (ii) unmodified titanium (as a refer-
ence to the current clinical treatment), and brushes modified 
with either (iii) FNIII7 _10 or (iv) RGD at equimolar ligand 
densities (0.9 pmol/cm2 ). In addition, a small number of 
implants with varying densities of FNIII7 _10 were analyzed. 
All implants were well-tolerated, and no complications were 
encountered during the course of the study. Following four 
weeks of implantation, the rat tibiae were harvested and ana-
lyzed for bone-implant contact by histomorphometry and 
implant mechanical fixation by pull-out testing. 
current clinical standard. 
A major advantage of the poly(OEGMA) brush system 
described in this work is the ability to precisely control the 
presentation of tethered ligands. Increases in the density of 
tethered FNIII7 _10 yielded linearly proportional increases in 
15 available bioactive ligand in vitro. Whether the density of 
tethered bioadhesive ligand modulated in vivo bone healing 
was evaluated by implanting samples with varying tethered 
densities of FNIII7 _10. Mechanical fixation increased with 
FNIII7 _10 surface density, displaying linear increases at low 
20 surface densities and reaching a saturation limit at high den-
sities (FIG. 15C). These results are accurately described by a 
simple hyperbolic relationship (R2 =0.87). This functional 
dependence is consistent with in vitro results for simple 
receptor-mediated phenomena such as adhesion strength. 
25 This is the first experimental study demonstrating finely 
tuned in vivo healing in response to engineered bioadhesive 
cues on material surfaces. 
The data demonstrate that conferring integrin binding 
specificity to engineered biomaterials regulates in vitro osteo-
Histological sections revealed extensive and contiguous 
bone matrix around FNIII7 _10-functionalized titanium 
implants. Less bone tissue was observed on the unmodified 
poly(OEGMA) brushes, poly(OEGMA) brushes with RGD 
tethered, and reference unmodified titanium implants, and the 
tissue present displayed a more porous morphology. Histo-
morphometric analysis of histological sections demonstrated 
a 70% enhancement in bone-implant contact area for FNIII7 _ 
10-functionalized implants compared to the RGD-tethered or 
unfunctionalized poly(OEGMA) brushes (p<0.02) (FIG. 
15A). Notably, the bone-implant contact area for the FNIII7 _ 
30 blastic differentiation of primary bone marrow stromal cells 
and in vivo bone healing and implant osseointegration. 
Importantly, this biomolecular strategy is based on surface 
engineering a robust non-fouling poly(OEGMA) polymer 
35 brush on clinical grade titanium, and therefore is applicable to 
existing biomedical implants. The integrin-specific biomate-
rial surfaces significantly enhanced in vivo implant integra-
tion and fixation compared to the current clinical standard 
(unmodified titanium) as well as biomimetic RGD-based sur-
40 face treatments. The data demonstrate that in vivo host 
10 group was significantly higher than that for the unmodified 
titanium implant (p<0.02). No evidence of foreign body giant 45 
cell persistence or fibrous capsule was observed in any of the 
sections. These findings demonstrate that controlled presen-
tation of the integrin-specific ligand FNIII7 _10 using this poly-
mer brush strategy significantly enhances implant integration 
into the host bone compared to implants presenting RGD- 50 
functionalized poly(OEGMA) brushes and the current clini-
cal standard (unmodified titanium). 
Mechanical fixation was used as an outcome measure of 
functional osseointegration. Pull-out mechanical testing 
revealed significantly higher mechanical fixation of the 55 
FNIII7 _10-functionalized implants over all other groups 
(p<0.03) (FIG. 15B). Implants coated with unmodified poly 
(OEGMA) brushes generated the lowest amount of bone 
apposition and mechanical fixation, suggesting that the poly-
mer brushes retain their non-fouling/bioresistant character in 60 
vivo. FNIII7 _10-functionalized implants exhibited a 2.9-fold 
enhancement in fixation over RGD-tethered implants 
(p<0.009) and approximately a 4-fold improvement com-
pared to the unmodified poly(OEGMA) brush coating 
(p<0.001). Notably, there were no differences in bone appo- 65 
sition or mechanical fixation between RGD-functionalized 
and unmodified poly(OEGMA) implants, demonstrating that 
responses to implanted devices can be tailored by engineering 
bioadhesive ligand specificity and density. Because of the 
central roles of integrin receptors in numerous tissue types, 
this strategy of engineering integrin specificity to implanted 
materials may have significant impact in the rational design of 
biomaterials for tissue engineering and regenerative medi-
cme. 
EXAMPLE 15 
Use of Engineered Surfaces to Treat Bone Defects 
The ability of GFOGER peptide (SEQ ID NO: 1 )-coated 
polymeric scaffolds to heal critical sized defects was exam-
ined. Critical sized defects do not heal during the lifetime of 
the animal, and therefore represent rigorous models for bone 
repair. A 8 mm segmental defect in the rat femur was used to 
evaluate bone repair. Three experimental groups were evalu-
ated: (i) empty defect controls, (ii) PCL scaffolds, and (iii) 
GFOGER peptide (SEQ ID NO:l)-coated PCL scaffolds. 
Polycaprolactone (PCL) is a clinically used polymer widely 
used in orthopaedic and soft tissue applications. Scaffolds 
were passively coated with GFOGER peptide (SEQ ID NO: 1) 
(20 µg/ml) as described above. Bone formation was assessed 
non-invasively via micro-computed tomography (micro-CT) 
at 4 and 12 weeks. Micro-CT analysis demonstrated an 
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enhancement in bone formation for GFOGER peptide (SEQ 
ID NO: 1 )-coated scaffolds compared to PCL and empty 
defects (FIG. 16). No differences in bone formation were 
observed between PCL and empty defects. These results 
demonstrate that the GFOGER peptide (SEQ ID NO: 1) coat-
ing enhances bone formation in a non-healing bone defect. 
stood by one of skill in the art to which the disclosed invention 
belongs. Publications cited herein and the materials for which 
they are cited are specifically incorporated by reference. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meanings as commonly under-
Those skilled in the art will recognize, or be able to ascer-
tain using no more than routine experimentation, many 
equivalents to the specific embodiments of the invention 
described herein. Such equivalents are intended to be encom-
passed by the following claims. 
<160> NUMBER OF SEQ ID NOS, 12 
<210> SEQ ID NO 1 
<211> LENGTH, 47 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic peptide 
<220> FEATURE, 
<221> NAME/KEY, MOD_RES 
<222> LOCATION, (26) .. (26) 
<223> OTHER INFORMATION, 4Hyp 
<400> SEQUENCE, 1 
Gly Gly Tyr Gly Gly Gly Pro Cys Gly Pro Pro Gly Pro Pro Gly Pro 
1 5 10 15 
Pro Gly Pro Pro Gly Pro Pro Gly Phe Pro Gly Glu Arg Gly Pro Pro 
20 25 30 
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Cys 
35 40 45 
<210> SEQ ID NO 2 
<211> LENGTH, 368 
<212> TYPE, PRT 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic sequence 
<400> SEQUENCE, 2 
Pro Leu Ser Pro Pro Thr Asn Leu His Leu Glu Ala Asn Pro Asp Thr 
1 5 10 15 
Gly Val Leu Thr Val Ser Trp Glu Arg Ser Thr Thr Pro Asp Ile Thr 
20 25 30 
Gly Tyr Arg Ile Thr Thr Thr Pro Thr Asn Gly Gln Gln Gly Asn Ser 
35 40 45 
Leu Glu Glu Val Val His Ala Asp Gln Ser Ser Cys Thr Phe Asp Asn 
50 55 60 
Leu Ser Pro Gly Leu Glu Tyr Asn Val Ser Val Tyr Thr Val Lys Asp 
65 70 75 80 
Asp Lys Glu Ser Val Pro Ile Ser Asp Thr Ile Ile Pro Ala Val Pro 
85 90 95 
Pro Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg 
100 105 110 
Val Thr Trp Ala Pro Pro Pro Ser Ile Asp Leu Thr Asn Phe Leu Val 
115 120 125 
Arg Tyr Ser Pro Val Lys Asn Glu Glu Asp Val Ala Glu Leu Ser Ile 
130 135 140 
Ser Pro Ser Asp Asn Ala Val Val Leu Thr Asn Leu Leu Pro Gly Thr 
145 150 155 160 
Glu Tyr Val Val Ser Val Ser Ser Val Tyr Glu Gln His Glu Ser Thr 
165 170 175 
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-continued 
Pro Leu Arg Gly Arg Gln Lys Thr Gly Leu Asp Ser Pro Thr Gly Ile 
180 185 190 
Asp Phe Ser Asp Ile Thr Ala Asn Ser Phe Thr Val His Trp Ile Ala 
195 200 205 
Pro Arg Ala Thr Ile Thr Gly Tyr Arg Ile Arg His His Pro Glu His 
210 215 220 
Phe Ser Gly Arg Pro Arg Glu Asp Arg Val Pro His Ser Arg Asn Ser 
225 230 235 240 
Ile Thr Leu Thr Asn Leu Thr Pro Gly Thr Glu Tyr Val Val Ser Ile 
245 250 255 
Val Ala Leu Asn Gly Arg Glu Glu Ser Pro Leu Leu Ile Gly Gln Gln 
260 265 270 
Ser Thr Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr 
275 280 285 
Pro Thr Ser Leu Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg 
290 295 300 
Tyr Tyr Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln 
305 310 315 320 
Glu Phe Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu 
325 330 335 
Lys Pro Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg 
340 345 350 
Gly Asp Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg Thr 
355 360 365 
<210> SEQ ID NO 3 
<211> LENGTH, 7 
<212> TYPE, PRT 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic peptide 
<400> SEQUENCE, 3 
Gly Arg Gly Asp Ser Pro Cys 
1 5 
<210> SEQ ID NO 4 
<211> LENGTH, 22 
<212> TYPE, PRT 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic sequence 
<400> SEQUENCE, 4 
Gly Arg Gly Asp Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly 
1 5 10 15 
Gly Pro His Ser Arg Asn 
20 
<210> SEQ ID NO 5 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 5 
ggccttcaag gttgtagccc 
<210> SEQ ID NO 6 
32 
20 
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<211> LENGTH, 16 
<212> TYPE, DNA 
33 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 
cccggccatg acggta 
<210> SEQ ID NO 7 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 7 
acgagctagc ggaccacatt 
<210> SEQ ID NO 8 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 8 
ccctaaacgg tggtgccata 
<210> SEQ ID NO 9 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 9 
tgacgctgga aagttggagt t 
<210> SEQ ID NO 10 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 10 
gccttgccct ctgcatgtc 
<210> SEQ ID NO 11 
<211> LENGTH, 5 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic construct 
<400> SEQUENCE, 11 
Pro His Ser Arg Asn 
1 5 
<210> SEQ ID NO 12 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic construct 
<220> FEATURE, 
<221> NAME/KEY, MOD_RES 
-continued 
34 
16 
20 
20 
21 
19 
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-continued 
<222> LOCATION, (3) .. (3) 
<223> OTHER INFORMATION, 4Hyp 
<400> SEQUENCE, 12 
Gly Phe Pro Gly Glu Arg 
1 5 
We claim: 
1. A gel comprising a peptide mimetic integrin ligand in an 
amount effective for promoting a2 ~ 1 -mediated or a ~ -me-
diated osseointegration in vivo between bone and a s~b~trate 
10 
in a subject in need thereof, wherein the peptide mimetic 15 
ligand is formulated into a gel wherein the peptide mimetic 
ligand is selected from the group consisting of the peptide 
comprising the amino acid sequence of SEQ ID NO: 1 or SEQ 
ID NO: 4, or the peptide consisting of the amino acid 
sequence of SEQ ID NO: 2, or a combination thereof. 
. 2. Th_e gel of claim 1, wherein the peptide mimetic integrin 
hgand 1s selected from the group consisting of a peptide 
comprising the amino acid sequence of SEQ ID NO: 1 or the 
peptide consisting of the amino acid sequence of SEQ ID NO 
:2, or a combination thereof. 
3 .. The gel o~ claim 1, wherein the gel promotes a2 ~ 1 -
medrnted osseomtegration between the bone and the sub-
strate. 
20 
25 
4. The gel of claim 1, wherein the gel promotes a ~ -
mediated osseointegration between the bone and the ~ub-
strate. 30 
5. The gel of claim 1, wherein the substrate is selected from 
the group consisting of bone, polymer and metal. 
6. The gel of claim 1, wherein the substrate is a substrate of 
a medical device. 
7. The gel of claim 6, wherein the medical device is 
selected from the group consisting of an implant, rod, pin, 
screw, brace, plate, prosthesis, and a tissue engineering scaf-
fold. 
8. The gel of claim 5, wherein the polymer comprises 
polycaprolactone. 
9. The gel of claim 1, wherein the peptide mimetic integrin 
ligand consists of GFOGER (SEQ ID NO: 1 ). 
10. The gel of claim 1, wherein the peptide mimetic inte-
grin ligand consists ofFNIII7 _10 (SEQ ID N0:2) . 
11. A method for treating a bone fracture in a subject in 
need thereof comprising administering the gel of claim 1 to 
the bone fracture in the subject, wherein the gel promotes 
repair of the bone fracture. 
12. A method for increasing fusion of bone surfaces in a 
su~ject in need thereof comprising administering the gel of 
claim 1 to the bone surfaces to be fused in the subject, wherein 
the gel promotes the fusion of the bone surfaces in the subject. 
13. A method for treating a bone fracture in a subject in 
need thereof comprising administering to the subject a medi-
cal device in combination with the gel of claim 1, wherein the 
combination of the medical device and the gel treat the bone 
defect. 
* * * * * 
